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Synthesis and pharmacological characterization of new
tetrahydrofuran based compounds as conformationally
constrained histamine receptor ligands†
Julian Bodensteiner,a Paul Baumeister,b Roland Geyer,b Armin Buschauer*b and
Oliver Reiser*a
A series of tetrahydrofuran based compounds with a bicyclic core that provides conformational restric-
tion were synthesized and investigated by radioligand displacement studies and functional [35S]GTPγS
binding assays at the human histamine receptor (hHR) subtypes. The amines 8a and 8b ((1S,3R,5S,6R)-
and ((1S,3S,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methanamine), exhibited submicro-
molar Ki values at the hH3R with 10-fold higher aﬃnities than their corresponding (6S)-epimers and
25- and >34-fold selectivity over the hH4R, respectively. Both compounds act as neutral antagonists at the
hH3R with KB values of 181 and 32 nM, respectively. The cyanoguanidines of the imidazole series and the
oxazole analogues turned out to be inactive at all hHR subtypes.
Introduction
Histamine is a biogenic amine that mediates its multiple physio-
logical eﬀects by the interaction with four known histamine
receptor (HR) subtypes, termed H1R, H2R, H3R and H4R, all
belonging to rhodopsin-like family A of G-protein-coupled
receptors (GPCRs).1
Activation of the H1R has long been known to be associated
with allergic conditions.1a,2 Antagonists of this receptor
subtype (popularly referred to as antihistamines) are used as
anti-allergic drugs since the 1940s.2 The H2R plays a pivotal
role in gastric acid secretion.3 H2R antagonists became
blockbuster drugs for the treatment of gastric and duodenal
ulcer and gastroesophagal reflux disease. The histamine H3R
is located predominantly in the central nervous system (CNS)
and acts both as a presynaptic autoreceptor4 modulating hista-
mine release and as an inhibitory heteroreceptor5 regulating
the release of multiple neurotransmitters, such as acetyl-
choline,6 dopamine,7 noradrenaline8 and serotonin.9 H3R
antagonists are being investigated as potential drugs for thera-
peutic applications against a variety of CNS disorders such as
Alzheimer’s disease, attention-deficit/hyperactivity disorder
(ADHD), epilepsy, migraine, narcolepsy, obesity, schizophrenia
and depression.10
Recently, the H3R antagonist pitolisant (tiprolisant) has
been introduced as an orphan drug for the treatment of narco-
lepsy.11 In the years 2000 and 2001, the H4R was identified and
cloned independently by several research groups.12 The H4R is
mainly expressed in blood forming organs and immunocytes
such as mast cells, basophils, eosinophils, monocytes, T-lym-
phocytes and dendritic cells.13 It is considered as a new thera-
peutic target for the modulation of various inflammatory and
immunological processes and disorders including bronchial
asthma, atopic dermatitis, allergic rhinitis, pruritus, colitis,
pain, cancer, rheumatoid arthritis and multiple sclerosis.14
Due to the significant sequence homology of the H4R with
the H3R (about 40% overall sequence identity and about 60%
within the transmembrane domains),12 many of the reported
H3R agonists and antagonists showed considerable H4R
activity as well.15 However, the development of more selective
ligands remains indispensable in order to further elucidate
the (patho-) physiological roles of H3R and H4R, which might
oﬀer new opportunities for the therapy of several diseases.
Since endogenous ligands such as histamine possess flexible
structures owing to rotations around single bonds, a reason-
able concept to improve potency and subtype selectivity is to
restrict the conformational flexibility.16 The aﬃnity at the
respective receptor subtypes increases if such conformationally
restricted analogues superimpose the bioactive conformation
of the natural ligand. In the case of membrane-bound proteins
where structural information is not known precisely, this
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strategy can be extended by the variation of stereochemistry
to explore the right spatial orientation and stereochemical
requirements of the pharmacophoric elements in the binding
pocket and to refine the models of ligand–receptor interaction.
This approach has been successfully applied for the devel-
opment of selective H3R and H4R ligands. Fig. 1 shows some
examples of histamine analogues comprising rigid carbo- and
heterocyclic cores. From a series of cyclopropane-based con-
formationally constrained histamine analogues with diverse
stereochemistry, Shuto et al. identified the “folded” cis-
analogue (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopro-
pane (1, AEIC) to be the most potent agonist at the hH3R (Ki =
1.3 nM, EC50 = 10 nM) which had virtually no eﬀect on the
H4R subtype.
17
Yamatodani et al. synthesized all imifuramine (2) stereo-
isomers and its corresponding cyanoguanidine analogues and
examined the binding aﬃnity and functional activity at the
human H3 and H4 receptors by in vitro studies.
18 Replacement
of the amino group by the cyanoguanidine moiety, which is
uncharged at physiological pH, resulted in a decrease in agon-
istic activity at the hH3R. In contrast, the potencies and intrin-
sic activities increased at the hH4R for most isomers. As a
result, OUP-16 (3) was identified as the first selective H4R
agonist.
Recently, we explored rigidified cyanoguanidine-type HR
ligands having a phenylene or a 1,4-cyclohexylene linker.19
While the phenylene linker yielded only very weakly active
compounds at both hH3R and hH4R, the less rigid 1,4-cyclo-
hexylene linker gave cis- and trans-configured molecules reveal-
ing EC50 or KB values ≥110 nM at the hH3R and hH4R. The
cis-configured isomers 4 preferred the hH4R and were partial
agonists, whereas the trans-isomers 5 were antagonists at the
hH4R. At the hH3R the trans-diastereomers 5 were superior to
the cis-isomers 4 by a factor of 10. Thus, previous results
suggest that the variation of conformational constraints and
stereochemical properties is a promising approach to further
explore the structure–activity and structure–selectivity relation-
ships of HR ligands.
As part of our eﬀorts to develop further potent and selective
H3 and H4 receptor ligands that may serve as pharmacological
tools and unravel the interactions within the binding
pockets, we herein describe the enantioselective synthesis and
pharmacological evaluation of potential HR ligands 6–9
containing a modified tetrahydrofuran spacer with a confor-
mationally constrained scaﬀold and diverse spatial orien-
tations (Scheme 1). The core structure consists of a fused ring
system and is formed by an asymmetric cyclopropanation reac-
tion, which gives rise to the bicyclic building block 10. The for-
mation of the imidazole moiety represents a key step in the
synthetic route and is realized by the conversion of aldehyde
11 via the TosMIC strategy. Finally, the amino group of 8
and the cyanoguanidino group of 6 are introduced by further
functional group interconversions including a Mitsunobu-type
Gabriel reaction. In parallel, analogues 9 and 7 with an
oxazole moiety as a potential bioisostere are synthesized and
pharmacologically characterized. All target compounds are
accessible as both enantiomers depending on the choice of
the respective chiral ligand in the asymmetric cyclopropana-
tion step.
Results and discussion
Chemistry
In the course of synthesizing various γ-butyrolactone contain-
ing natural products20 we had previously developed the
asymmetric cyclopropanation of furan-2-carboxylic acid ester
12 derived from commercially available 2-furoic acid
(Scheme 2).21 The reaction proceeded with ethyl diazoacetate
in the presence of catalytic copper(I)-isopropyl bis(oxazoline)
with high enantio- and diastereoselectivity to give bicyclic com-
pound 10. The double bond in 10 was hydrogenated accord-
ingly using palladium on charcoal in EtOAc.22 The
hydrogenation proceeds via syn-addition exclusively from the
less hindered convex face of the bicyclic framework to form 13
as a single stereoisomer after recrystallization. A directed
thus highly chemoselective reduction of the methyl ester to
alcohol 14, being assisted by the adjacent furan ring oxygen,
was followed by a Dess–Martin oxidation to give aldehyde 15.
Subsequent base-induced [3 + 2]cycloaddition with p-toluene-
sulfonylmethyl isocyanide (TosMIC) aﬀorded tosyloxazoline 16
as a mixture of diastereomers.23 The conversion to the corres-
ponding imidazole 17 by treatment with ammonia according
to Horne et al. turned out to be not feasible.24 Also several
Fig. 1 Conformationally restricted histamine receptor ligands.
Scheme 1 Retrosynthetic analysis of the target compounds.
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other TosMIC based methods25 starting from aldehyde 15 were
not successful. Any unexpected ring-opening reaction was
ruled out by diﬀerent test reactions. However, it could not be
totally excluded that the ester moiety was interfering with the
imidazole forming reaction. To circumvent the diﬃculties con-
cerning the introduction of the imidazole ring we decided to
displace the ethyl ester group by a benzyl ether protecting
group which is inert under the prevailing basic conditions. For
this reason, the primary alcohol of compound 14 was TBS-
protected (Scheme 3). The ester group of intermediate 18 was
reduced with LiAlH4 and the resulting primary alcohol 19 was
protected with benzyl bromide. After TBAF-mediated cleavage
Scheme 2 Reagents and conditions: (a) ref. 21; (b) ref. 22; (c) LAH, THF, 0 °C, 45 min, 87%; (d) Dess–Martin periodinane, DCM, rt, 1 h, 88%; (e) TosMIC, NaCN,
EtOH, rt, 1 h, 70%; R = OEt, OMe, NH2.
Scheme 3 Reagents and conditions: (a) NEt3, TBSCl, DMAP, DCM, rt, 18 h, 95%; (b) LAH, THF, 0 °C, 45 min, 95%; (c) NaH, BnBr, DMF, 0 °C to rt, 2 h, 85%; (d) TBAF,
THF, rt, 13 h, 95%; (e) Dess–Martin periodinane, DCM, rt, 2 h, 90%; (f ) TosMIC, NaCN, EtOH, rt, 2 h, 77%; (g) NH3 saturated in MeOH, 95 °C, sealed pressure tube,
16 h, (24a : 24b = 5 : 1); (h) ethyl chloroformate, pyridine, DMAP, benzene, 50 °C, 10 min, 73%; (i) Pd(OH)2–C, cyclohexene, EtOH, reﬂux, 1 h, 73%; ( j) PPh3, phthali-
mide, DIAD, THF, rt, 18 h, 29%; (k) hydrazine hydrate, EtOH, reﬂux, 1 h, 77%; (l) (i) dimethyl N-cyanodithioiminocarbonate, MeOH, rt, 18 h; (ii) MeNH2 in EtOH, rt,
18 h, 69% over two steps; (m) PPh3, phthalimide, DIAD, THF, rt, 18 h, 27%; (n) hydrazine hydrate, EtOH, reﬂux, 1.5 h, 68%; (o) (i) dimethyl N-cyanodithioiminocarbo-
nate, MeOH, rt, 18 h; (ii) MeNH2 in EtOH, rt, 18 h, 64% over two steps.
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of the silylether, oxidation of alcohol 21 by means of Dess–
Martin periodinane aﬀorded aldehyde 22 which underwent
cycloaddition with TosMIC.23 The resulting oxazoline diaster-
eomers 23 were treated with a solution of ammonia in MeOH
at elevated temperature in a sealable pressure tube giving rise
to the desired imidazole 24 in up to 68% yield.24 Besides the
expected imidazole isomer 24a, epimer 24b was identified as
well due to the basic and high temperature conditions applied.
Best results (24a : 24b = 5 : 1) were obtained by heating at
95 °C, while higher temperatures caused increased epimeriza-
tion. Following the protocol of Harusawa et al., imidazole 24
was converted to its base-sensitive carbamate-protected deriva-
tive 25 using ethyl chloroformate to improve the solubility pro-
perties and to facilitate the separation of the epimers at a later
stage of the reaction sequence.26 Cleavage of the benzyl ether
to give alcohol 26 was realized by catalytic transfer hydrogen-
ation using palladium hydroxide on carbon and cyclohexene
as the hydrogen donor.27 At this point, separation of the
isomers was necessary since the next step provided several
side-products, which were otherwise tedious to separate and to
characterize. To displace the hydroxyl group of the (3R)-
isomer 26a with an amino moiety, a phthaloylimination under
Mitsunobu conditions and subsequent hydrazinolysis were
performed.28 By treating 26a with phthalimide in the presence
of PPh3 and DIAD, the desired phthalimide 27a was obtained
in low yield. Further ring-opening gave phthalimides 28 as a
mixture of epimers due to a cyclopropylcarbinyl–homoallylic
rearrangement (Scheme 4).29 Diene 29 was observed as well
but was not separable from the triphenylphosphine oxide
byproduct. In order to optimize the conditions for the prepa-
ration of the desired phthalimide 27a diﬀerent conditions
were screened using model compound 19. However, the
change of the addition order of the reagents, variation in the
relative reagent concentrations and diﬀerent reaction temp-
eratures and solvents did not lead to a significantly improved
ratio of products. Cleavage of the phthalimide moiety of com-
pound 27a by means of hydrazinolysis proceeded smoothly
with simultaneous removal of the base-sensitive carbamate
protection group at the imidazole ring to give the desired
target compound amine 8a (Scheme 3). The conversion to the
analogous cyanoguanidine-containing compound 6a required
two additional steps. First, amine 8a was treated with an
excess of dimethyl N-cyanodithioiminocarbonate in MeOH to
furnish an isothiourea compound which was then directly con-
verted without purification to the desired cyanoguanidine 6a
by adding an ethanolic solution of MeNH2.
26
The respective (3S)-configured target compounds, amine 8b
and cyanoguanidine 6b, were derived from the corresponding
(3S)-configured alcohol 26b running through an analogous
synthetic pathway via phthalimide 27b. Consequently, the
(6R)-configured target molecules, amines 6a and 6b and the
cyanoguanidines 8a and 8b could be prepared. Additionally,
by employing the (R,R)-isopropyl bis(oxazoline) ligand in
the cyclopropanation step, the respective (6S)-enantiomers,
amines 8c and 8d and cyanoguanidines 6c and 6d, were
accessible.
As a putative bioisostere of the imidazole, an oxazole
moiety was introduced by elimination of p-toluene sulfinic
acid from tosyloxazoline 16 accompanied by transesterification
of the ethyl ester group to give compound 33 (Scheme 5).23
Subsequent reduction with LiAlH4 furnished alcohol 34. The
hydroxy group was converted into a phthalimide moiety via a
Mitsunobu reaction.28 In comparison to the similar transfor-
mation of 26a to 27a described above, the reaction proceeded
with the formation of smaller amounts of ring opening pro-
ducts and this with higher yield to the desired 35 (55% vs.
29% for 27a) for reasons that are not clear. Hydrazinolysis gave
rise to the amine 9a. The corresponding cyanoguanidine 7a
was readily obtained by converting the amino group with
dimethyl N-cyanodithioiminocarbonate to isothiourea 36 fol-
lowed by treatment with MeNH2 in EtOH.
26 In turn, the appli-
cation of the enantiomeric isopropyl bis(oxazoline) ligand in
the asymmetric cyclopropanation reaction provided access to
the enantiomeric target compounds, 9b and 7b, as well.
Pharmacology
All the synthesized target compounds depicted in Fig. 2 were
investigated at the hH1R, hH2R, hH3R and hH4R in radioligand
binding assays using membrane preparations of Sf9 insect
cells coexpressing the hH1R + RGS4, hH2R−Gsαs fusion
protein, hH3R + Gαi2 + Gβ1γ2 or hH4R + Gαi2 + Gβ1γ2, respect-
ively. Those compounds having submicromolar Ki values were
investigated for agonism or antagonism at hH3R and hH4R
subtypes in functional [35S]GTPγS assays using the above
Scheme 4 Mitsunobu reaction.
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mentioned membrane preparations. Intrinsic activities (α)
refer to the maximal response induced by the standard agonist
histamine (α = 1.0). Compounds identified to be inactive as
agonists (α < 0.13 or negative values, respectively, determined
in the agonist mode) were investigated in the antagonist
mode. The corresponding KB values of neutral antagonists
were determined from the concentration-dependent inhibition
of the histamine-induced increase in [35S]GTPγS binding.
In agreement with the findings of Hashimoto et al., the
amines 8a–d exhibited significantly stronger binding aﬃnities
at the hH3R than at the hH4R (Table 1). At the hH3R the (6R)-
configured eutomers 8a and 8b showed submicromolar Ki
values. Both compounds were about 10-fold more potent than
their (6S)-configured distomers 8c and 8d. At the hH4R, com-
pounds 8a and 8d, having the (3R)-configuration, exhibited
weak binding aﬃnities with low micromolar Ki values. In con-
trast to this, the respective (3S)-configured epimers 8b and 8c
did not show any significant binding (Ki > 10 000 nM) at this
receptor subtype. An unambiguous preference for either the
folded isomers ((3R,6R)-cis-8a and (3S,6S)-cis-8d) or the
extended analogues ((3S,6R)-trans-8b and (3R,6S)-trans-8c) was
not observed at both receptor subtypes. As a result, binding
aﬃnities for the amines 8a, 8b, 8c and 8d at the hH3R were 25,
>34, >4 and 3-fold higher than at the hH4R subtype, respect-
ively. Additionally, 8a–d were devoid of activity at the hH1R
and hH2R. 8a and 8b were investigated for their functional
activity at the hH3R. In contrast to imifuramine and its stereo-
isomers, which were all reported to act as full agonists at the
H3R,
18 8a and 8b turned out to be almost neutral antagonists
with KB values of 181 and 32 nM, respectively. The elongated
spacer and the diﬀerent spatial arrangement of the pharmaco-
phoric elements were tolerated to a certain extent for the con-
formationally constrained amines compared to Hashimoto’s
THF-based ligands. At both HR subtypes comparable Ki values
were determined, especially at the hH3R, but the quality of
action was diﬀerent.
In contrast, the cyanoguanidines 6a–d turned out to be
inactive (Ki > 10 000 nM) at all four HR subtypes, notably at the
H4R. In this case, the orientation of the pharmacophoric
elements, provided by the bicyclic core, is detrimental for
receptor binding. An increase in hH4R aﬃnity by replacement
of the amino group with a cyanoguanidino moiety – as
observed for the imifuramine based compounds18 – was not
achieved.
The synthesized oxazoles 9a, 9b, 7a and 7b were investi-
gated in radioligand binding assays at the hH1R and hH2R
Scheme 5 Reagents and conditions: (a) K2CO3, MeOH, reﬂux, 0.5 h, 31%; (b) LAH, THF, 0 °C, 0.5 h, 71%; (c) PPh3, phthalimide, DIAD, THF, 0 °C, 0.5 h, 55%; (d)
hydrazine hydrate, EtOH, reﬂux, 1.5 h, 72%; (e) dimethyl N-cyanodithioiminocarbonate, EtOH, rt, 18 h, quant.; (f ) MeNH2 in EtOH, rt, 18 h, 90%.
Fig. 2 Synthesized target compounds.
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subtypes and in functional [35S]GTPγS assays at the hH3R and
hH4R subtypes but did not reveal any activity at all receptor
subtypes. Even oxazole 9a, whose imidazole analogue 8a
exhibited submicromolar aﬃnities at the hH3R, was inactive at
the hH3R. Thus, in this class of HR ligands, independently
from the other structural modifications, the oxazole ring
proved to be inappropriate as a bioisostere of an imidazole
ring. This is presumably due to a diﬀerent H-bond donor–
acceptor interaction pattern and the reduced basicity of the
oxazole moiety compared to the imidazole ring.
Conclusion
In conclusion, we have synthesized and pharmacologically
characterized a set of bicyclic imifuramine analogues as poten-
tial histamine receptor ligands. In the imidazole series, the
conformationally constrained amines and cyanoguanidines
were obtained in 15 and 17 steps, respectively, starting from
commercially available furan-2-carboxylic acid. The oxazole
analogues could be realized in 10 and 12 steps, respectively.
The synthetic pathways deliver valuable information about
the scope and limitations of the rigid bicyclic core in terms
of chemical transformations of its substituents. In the case of
the imidazole compounds the introduction of the aromatic
heterocyles by TosMIC chemistry gave rise to additional
epimers. As a result, diﬀerent isomers with distinct stereoche-
mical orientations could be achieved. Pharmacological investi-
gations at the human HR subtypes revealed aﬃnities of the
amines 8 at the hH3R in a comparable range as reported for
the imifuramine derived stereoisomers, but with diﬀerent
qualities of action. Especially 8b showed high subtype selecti-
vity for the hH3R with no aﬃnity for the hH4R. In agreement
with these findings and in contrast to the cyanoguanidine 3
bearing the tetrahydrofuran moiety, the cyanoguanidines 6
were devoid of activity at the hH4R as well. These results
suggest that the 2-oxabicyclo[3.1.0]hexane framework used in
this study might be a promising scaﬀold for the hH3R selective
ligands. Replacement of the imidazole ring by an oxazole
substituent as a potential bioisostere led to loss of activities
at HR subtypes. Apparently, the H-bond donor and acceptor
properties and the basicity of the oxazole ring are
inappropriate.
These findings contribute to the objective of further eluci-
dating the structural requirements of selective histamine H3
and H4 receptor ligands that may help to enable the synthesis
of tailored compounds as novel pharmacological tools and
potential drugs with the intended quality of action.
Table 1 Aﬃnities, potencies and eﬃcacies of the synthesized amines and cyanoguanidines at the hHR subtypes determined in radioligand binding studiesa and
functional [35S]GTPγS assaysb
Compound Config.
hH1R hH2R hH3R hH4R
Ki (nM) N Ki (nM) N
Ki (nM)
α N
Ki (nM)
α N(KB or EC50
b (nM)) (KB or EC50
b (nM))
Histaminec 200 5 × 104 10 7.9(13)
(5.0) 1.00 1.00
Imifuramine (2)d — — 229 891
(45) 1.04 (1995) 0.70
OUP-16 (3)d — — 2188 126
(3261) 0.79 (78) 0.99
8a 3R,6R Inactive 2 Inactive 2 231 ± 106 3 5787 ± 853 2
(181 ± 119) −0.10 2
8b 3S,6R Inactive 2 Inactive 2 295 ± 154 2 >10 000 2
(32 ± 17) −0.12 2
8c 3S,6S Inactivee 2 Inactivee 2 2326 ± 982 2 >10 000 2
8d 3R,6S Inactivee 2 Inactivee 2 2818 ± 1823 2 8415 ± 417 2
6a 3R,6R Inactivee 2 Inactivee 2 Inactive 2 Inactive 2
6b 3S,6R Inactivee 2 Inactivee 2 Inactive 2 Inactive 2
6c 3S,6S Inactivee 2 Inactivee 2 Inactive 2 Inactive 2
6d 3R,6S Inactivee 2 Inactivee 2 Inactive 2 Inactive 2
9a 3R,6R Inactivee 2 Inactivee 2 (Inactive) −0.08 2 (Inactive) 0.02 2
9b 3S,6S Inactivee 2 Inactivee 2 (Inactive) −0.06 2 (Inactive) 0.13 2
7a 3R,6R Inactivee 2 Inactivee 2 (Inactive) 0.07 2 (Inactive) −0.03 2
7b 3S,6S Inactivee 2 Inactivee 2 (Inactive) −0.07 2 (Inactive) −0.06 2
aDetermination of hH1R binding by displacement of [
3H]pyrilamine (5 nM) from Sf9 cell membranes expressing the hH1R + RGS4, hH2R
binding by displacement of [3H]UR-DE257 (30 nM) from Sf9 cell membranes expressing the hH2R−Gsαs, hH3R binding by displacement of [3H]
Nα-methylhistamine (3 nM) or [3H]histamine (15 nM) from Sf9 cell membranes expressing the hH3R + Gαi2 + Gβ1γ2 or hH4R binding by
displacement of [3H]histamine (15 nM) from Sf9 cell membranes expressing the hH4R + Gαi2 + Gβ1γ2 was determined as described in the
Pharmacology section. b Functional [35S]GTPγS binding assays with membrane preparations of Sf9 cells expressing the hH3R + Gαi2 + Gβ1γ2 or the
hH4R + Gαi2 + Gβ1γ2 were performed as described in the Pharmacology section. a,bLigands concentrations from 1 nM to 1 mM as appropriate to
generate saturated concentration/response curves. Compounds showing no eﬀect in this range were referred to as inactive. N gives the number of
independent experiments performed in triplicate each. The intrinsic activity (α) of histamine was set to 1.00 and α values of other compounds
were referred to this value. The α values of neutral antagonists and inverse agonists were determined at a concentration of 10 μM. The KB values
of neutral antagonists were determined in the antagonist mode versus histamine (100 nM) as the agonist. c Values taken from Igel et al.30 d Values
for hH3R and hH4R taken from Hashimoto et al.
18 eMeasured at a ligand concentration of 100 µM.
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Experimental
Chemistry
Analytical HPLC analysis was performed with a system from
Merck (Darmstadt, Germany) consisting of a L-5000 controller,
a 655A-12 pump, a 655A-40 autosampler and a L-4250 UV-VIS
detector on a Eurospher-100 C18 column (250 × 4 mm, 5 μm,
Knauer, Berlin, Germany) at a flow rate of 0.8 mL min−1. Mix-
tures of acetonitrile and 0.05% aq. TFA were used as the
mobile phase. Helium degassing was used throughout. Com-
pound purities were calculated as the percentage peak area of
the analyzed compound by UV detection at 210 nm. HPLC con-
ditions, retention times (tR), capacity factors (k′ = (tR − t0)/t0)
and purities of the synthesized compounds are listed in the
ESI.†
All reactions were carried out in oven-dried glassware under
atmospheric conditions unless otherwise stated. All solvents
were dried and distilled prior to use. Thin layer chromato-
graphy (TLC) was performed using silica gel 60 F254 alu-
minium plates (Merck). Eluted plates were visualized using a
254 nm UV lamp and/or by treatment with a suitable stain fol-
lowed by heating. Column chromatography was performed on
silica gel 60 (0.063–0.200 mm, Merck). 1H- and 13C-NMR
spectra were recorded on a Bruker Avance 300 (300 MHz for
1H, 75 MHz for 13C), Bruker Avance III 400 “Nanobay”
(400 MHz for 1H, 101 MHz for 13C) or Avance III 600 (600 MHz
for 1H, 151 MHz for 13C) FT-NMR-spectrometer. Chemical
shifts are reported in parts per million (ppm). ATR-IR
spectroscopy was carried out on a Biorad Excalibur FTS 3000
spectrometer equipped with a Specac Golden Gate Diamond
Single Reflection ATR-system. Optical rotations were measured
on a P8000T polarimeter (Kruess) at a wavelength of 589 nm in
a 5 cm cell of 0.7 mL volume in the specified solvent. Con-
centrations are indicated in [g/100 mL]. The melting points
were measured on a Büchi SMP-20 apparatus in a silicon oil
bath. Values thus obtained were not corrected. Mass spec-
trometry was performed on a Varian MAT 311A, Finnigan MAT
95, Thermoquest Finnigan TSQ 7000 or Agilent Technologies
6540 UHD Accurate-Mass Q-TOF LC/MS. The percentage set
in brackets gives the peak intensity related to the basic peak
(I = 100%). High resolution mass spectrometry (HRMS): the
molecular formula was proven by the calculated precise mass.
Elemental analyses (C, H, N, Heraeus Elementar Vario EL III)
were performed by the Analytical Department of the University
of Regensburg.
Preparative HPLC was performed at room temperature with
a system from Knauer (Berlin, Germany) consisting of two
K-1800 pumps, a K-2001 detector (UV detection at 220 nm)
and a RP-column (VP Nucleodur 100-5 C18 ec, 250 × 21 mm,
5 μm, Macherey Nagel, Düren, Germany) at a flow rate of
15 mL min−1 or a RP-column (YMC-Triat C18, 150 × 20.0 m,
5 µm, YMC Europe GmbH, Dinslaken, Germany) at a flow rate
of 10 mL min−1. Mixtures of acetonitrile and 0.1% aq. TFA
were used as the mobile phase in the case of the Nucleodur
column and mixtures of acetonitrile and 0.1% aq. NH3 were
used as the mobile phase in the case of the YMC-Triat column.
Acetonitrile was removed from the eluates under reduced
pressure at 45 °C prior to lyophilization.
Preparation of 1-(((1S,3R,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabi-
cyclo[3.1.0]hexan-6-yl)methyl)-2-cyano-3-methylguanidine (6a).
A solution of compound 8a (5.0 mg, 0.028 mmol) and
dimethyl N-cyanodithioiminocarbonate (9.9 mg, 0.067 mmol,
2.4 equiv.) in anhydrous MeOH (0.55 mL) was stirred at room
temperature for 18 h. Then a 33% solution of MeNH2 in EtOH
(0.52 mL) was added and stirred for 18 h at room temperature.
The solvent was evaporated to give a residual oil that was puri-
fied by column chromatography (EtOAc–MeOH 4 : 1) to give
compound 6a (5.0 mg, 0.019 mmol, 69%) as a colorless oil. For
pharmacological testing the product was further purified by
preparative HPLC (YMC-Triat column, mobile phase: MeCN,
0.1% aq. NH3).
Rf = 0.19 (EtOAc–MeOH 4 : 1); [α]
20
D = +18.2 (MeOH, c = 0.2);
1H-NMR (300 MHz, MeOD): δH = 7.62 (d, J = 1.0 Hz, 1H), 6.96
(s, 1H), 5.38 (t, J = 7.9 Hz, 1H), 3.89 (dd, J = 6.4, 1.1 Hz, 1H),
3.05 (dd, J = 14.3, 6.9 Hz, 1H), 2.91 (dd, J = 14.3, 7.9 Hz, 1H),
2.79 (s, 3H), 2.55 (dt, J = 12.8, 7.4 Hz, 1H), 2.06 (ddd, J = 12.8,
8.1, 1.9 Hz, 1H), 1.74–1.63 (m, 1H), 1.46–1.36 (m, 1H);
13C-NMR (75 MHz, MeOD): δC = 161.96 (Cq), 140.02 (Cq),
136.79 (+), 120.08 (Cq), 117.42 (+), 83.90 (+), 65.43 (+), 42.58
(−), 36.41 (−), 33.19 (+), 28.67 (+), 24.09 (+); IR (ATR): ν˜ (cm−1)
= 3268 (br), 2928, 2160, 1729, 1575, 1485, 1448, 1404, 1369,
1247, 1174, 1097, 1066, 1030, 988, 838, 752, 716, 618, 570; MS
(ESI): m/z (%) = 163.1 [M+ΔC3H5N4] (60), 261.1 [MH+] (100);
HRMS (ESI): calcd for C12H17N6O [MH
+] 261.1458, found
261.1458.
Preparation of 1-(((1S,3S,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabi-
cyclo[3.1.0]hexan-6-yl)methyl)-2-cyano-3-methylguanidine (6b).
A solution of compound 8b (3.0 mg, 0.017 mmol) and
dimethyl N-cyanodithioiminocarbonate (8.2 mg, 0.05 mmol,
3.0 equiv.) in anhydrous MeOH (0.34 mL) was stirred at
room temperature for 18 h. Then a 33% solution of MeNH2
in EtOH (0.31 mL) was added. The resulting mixture
was stirred for 18 h at room temperature. The solvent was evap-
orated to give a residual oil that was purified by column
chromatography (EtOAc–MeOH 4 : 1) to give compound 6b
(2.8 mg, 0.011 mmol, 64%) as a colorless oil. For pharmaco-
logical testing the product was further purified by preparative
HPLC (YMC-Triat column, mobile phase: MeCN, 0.1% aq.
NH3).
Rf = 0.19 (EtOAc–MeOH 4 : 1); [α]
20
D = +36.7 (MeOH, c = 0.1);
1H-NMR (600 MHz, MeOD): δH = 7.62 (s, 1H), 7.00 (s, 1H), 4.76
(dd, J = 8.7, 7.7 Hz, 1H), 3.94 (dd, J = 5.7, 1.1 Hz, 1H), 3.07 (dd,
J = 14.3, 6.9 Hz, 1H), 2.97 (dd, J = 14.3, 7.7 Hz, 1H), 2.81 (s,
3H), 2.29 (dd, J = 12.4, 7.1 Hz, 1H), 2.25–2.19 (m, 1H),
1.62–1.59 (m, 1H), 1.59–1.54 (m, 1H); 13C-NMR (151 MHz,
MeOD): δC = 162.01 (Cq), 136.88 (+), 120.08 (Cq), 63.74 (+),
49.57 (+), 42.71 (−), 35.51 (−), 28.69 (+), 22.28 (+), 21.94 (+), Im-
C5 and Im-C4 signals too weak to be observed; IR (ATR):
ν˜ (cm−1) = 2934 (br), 2163, 1582, 1486, 1410, 1372, 1322, 1175,
1121, 1100, 922, 892, 833, 689, 617; MS (ESI): m/z (%) = 261.1
[MH+] (100), 521.2 [2MH+] (15); HRMS (ESI): calcd for
C12H17N6O [MH
+] 261.1458, found 261.1457.
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Preparation of 2-cyano-1-methyl-3-(((1S,3R,5S,6R)-3-(oxazol-
5-yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl) guanidine (7a).
Compound 36 (26 mg, 0.09 mmol) was dissolved in a 33%
solution of MeNH2 in EtOH (2 mL) and stirred for 18 h at
room temperature. The solvent was evaporated under reduced
pressure. Purification by column chromatography (DCM then
DCM–MeOH 9 : 1) aﬀorded compound 7a (22 mg, 0.08 mmol,
90%) as a colorless oil.
Rf = 0.32 (DCM–MeOH 9 : 1); [α]
20
D = +18.9 (DCM, c = 1.0);
1H-NMR (400 MHz, CDCl3): δH = 7.84 (s, 1H), 6.96 (s, 1H), 5.64
(s, 1H), 5.43 (dd, J = 8.3, 7.4 Hz, 1H), 5.20 (s, 1H), 3.95 (dd, J =
6.3, 1.0 Hz, 1H), 3.24–3.13 (m, 1H), 2.95–2.86 (m, 1H), 2.85 (d,
J = 4.9 Hz, 3H), 2.62 (ddd, J = 13.1, 8.6, 7.0 Hz, 1H), 2.14 (ddd,
J = 13.1, 7.0, 1.4 Hz, 1H), 1.73–1.67 (m, 1H), 1.37 (tdd, J = 8.0,
4.0, 1.0 Hz, 1H); 13C-NMR (101 MHz, CDCl3): δC = 160.65 (Cq),
151.72 (Cq), 151.44 (+), 124.01 (+), 118.53 (Cq), 78.46 (+), 65.08
(+), 42.03 (−), 33.91 (−), 30.74 (+), 28.57 (+), 23.15 (+); IR (ATR):
ν˜ (cm−1) = 3292 (br), 2954, 2929, 2165, 1583, 1507, 1453, 1409,
1370, 1174, 1103, 1028, 963, 838, 717; MS (ESI): m/z (%) =
262.1 (25) [MH+], 523.2 (100) [2MH+]; HRMS (EI): calcd for
C12H15N5O2 [M
+˙] 261.1226, found 261.1222.
Preparation of ((1S,3R,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicy-
clo[3.1.0]hexan-6-yl)methanamine (8a). A solution of phthali-
mide 27a (30 mg, 0.079 mmol) and hydrazine hydrate (21 µL,
0.43 mmol, 5.4 equiv.) in anhydrous EtOH (1.6 mL) was
refluxed for 1 h. The solvent was removed under reduced
pressure and the residue was purified by column chromato-
graphy (MeOH–saturated NH3 in MeOH 95 : 5) to aﬀord com-
pound 8a (11 mg, 0.061 mmol, 77%) as a colorless amorphous
solid. For pharmacological testing the product was further
purified by preparative HPLC (Nucleodur column, mobile
phase: MeCN, 0.1% aq. TFA).
Rf = 0.20 (MeOH–saturated NH3 in MeOH 95 : 5); [α]
20
D =
+36.4 (MeOH, c = 0.5); 1H-NMR (300 MHz, MeOD): δH = 7.61
(d, J = 1.0 Hz, 1H), 6.95 (s, 1H), 5.38 (t, J = 7.9 Hz, 1H), 3.82
(dd, J = 6.4, 1.2 Hz, 1H), 2.63–2.49 (m, 1H), 2.38 (d, J = 7.3 Hz,
2H), 2.04 (ddd, J = 12.7, 8.0, 1.9 Hz, 1H), 1.61 (tdd, J = 6.2, 3.9,
1.9 Hz, 1H), 1.26 (tdd, J = 7.4, 4.0, 1.1 Hz, 1H); 13C-NMR
(75 MHz, MeOD): δC = 136.71 (+), 117.55 (+), 83.87 (+), 65.46
(+), 42.61 (−), 36.63 (−), 36.07 (+), 23.99 (+), Im-Cq-signal too
weak to be observed; IR (ATR): ν˜ (cm−1) = 3094 (br), 2937, 2869,
2625, 1573, 1454, 1414, 1361, 1306, 1177, 1098, 1067, 1028,
980, 912, 841, 632, 540, 497; MS (ESI): m/z (%) = 163.1 (100)
[MH+ΔNH3], 180.1 (19) [MH+], 359.2 (11) [2MH+]; HRMS (ESI):
calcd for C9H14N3O [MH
+] 180.1131, found 180.1130.
8a·2TFA: 1H-NMR (600 MHz, MeOD): δH = 8.83 (d, J =
1.0 Hz, 1H), 7.45 (s, 1H), 5.51 (t, J = 7.4 Hz, 1H), 4.10 (dd, J =
6.3, 0.7 Hz, 1H), 2.90–2.63 (m, 3H), 2.14 (ddd, J = 13.1, 7.0,
1.5 Hz, 1H), 1.92–1.87 (m, 1H), 1.31–1.26 (m, 1H); 13C-NMR
(151 MHz, MeOD): δC = 163.10 (Cq, TFA), 162.87 (Cq, TFA),
136.63 (+), 135.90 (Cq), 119.17 (+, TFA), 117.23 (+, TFA), 116.76
(+), 79.55 (+), 65.65 (+), 40.61 (−), 35.88 (−), 29.34 (+), 24.45 (+).
Preparation of ((1S,3S,5S,6R)-3-(1H-imidazol-5-yl)-2-oxabicy-
clo[3.1.0]hexan-6-yl)methanamine (8b). A solution of phthali-
mide 27b (16 mg, 0.042 mmol) and hydrazine hydrate (11 µL,
0.23 mmol, 5.4 equiv.) in anhydrous EtOH (0.85 mL) was
refluxed for 1.5 h. The solvent was removed under reduced
pressure and the residue was purified by column chromato-
graphy (MeOH–saturated NH3 in MeOH 97 : 3) to aﬀord com-
pound 8b (5.1 mg, 0.028 mmol, 68%) as a colorless
amorphous solid. For pharmacological testing the product was
further purified by preparative HPLC (Nucleodur column,
mobile phase: MeCN, 0.1% aq. TFA).
8b·2TFA: Rf = 0.20 (MeOH–saturated NH3 in MeOH 95 : 5);
[α]20D = +5.5 (DCM, c = 0.2);
1H-NMR (600 MHz, MeOD): δH =
8.88 (d, J = 1.3 Hz, 1H), 7.50 (d, J = 0.9 Hz, 1H), 4.94 (dd, J =
8.9, 7.5 Hz, 1H), 4.14 (dd, J = 5.8, 1.2 Hz, 1H), 2.82 (dd, J =
13.4, 8.0 Hz, 1H), 2.77 (dd, J = 13.4, 7.8 Hz, 1H), 2.51 (dd, J =
12.7, 7.4 Hz, 1H), 2.22 (ddd, J = 12.8, 9.1, 5.6 Hz, 1H),
1.83–1.79 (m, 1H), 1.56 (tdd, J = 7.9, 3.9, 1.1 Hz, 1H). 13C-NMR
(151 MHz, MeOD): δC = 162.80 (Cq, TFA), 162.56 (Cq, TFA),
136.08 (Cq), 134.59 (+), 119.04 (+, TFA), 117.45 (+), 117.11
(+, TFA), 72.81 (+), 64.08 (+), 40.76 (−), 35.51 (−), 22.52 (+),
20.51 (+); IR (ATR): ν˜ (cm−1) = 3240 (br), 2935, 2873, 2627,
1580, 1492, 1420, 1372, 1312, 1180, 1101, 899, 840, 630, 540;
MS (ESI): m/z (%) = 180.0 (100) [MH+], 359.2 (20) [2MH+];
HRMS (ESI): calcd for C9H14N3O [MH
+] 180.1131, found
180.1133.
Preparation of ((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo-
[3.1.0]hexan-6-yl)methanamine (9a). A solution of phthali-
mide 35 (60 mg, 1.19 mmol) and hydrazine hydrate (48 mg,
0.97 mmol, 5 equiv.) in EtOH (4 mL) was refluxed for 1.5 h and
then cooled in an ice bath. The white precipitate was removed
by filtration through a Celite pad. The filtrate was concentrated
in vacuo. Column chromatography (DCM–saturated NH3 in
MeOH 20 : 1) aﬀorded compound 9a (25 mg, 0.10 mmol, 72%)
as a colorless solid.
Mp = 51 °C; Rf = 0.32 (DCM–saturated NH3 in MeOH 9 : 1);
[α]20D = +36.2 (DCM, c = 1.0);
1H-NMR (400 MHz, CDCl3): δH =
7.80 (s, 1H), 6.93 (s, 1H), 5.41 (dd, J = 8.1, 7.4 Hz, 1H), 3.82
(dd, J = 6.3, 1.2 Hz, 1H), 2.58 (ddd, J = 12.9, 8.6, 7.0 Hz, 1H),
2.51–2.39 (m, 2H), 2.11 (ddd, J = 12.9, 6.9, 1.5 Hz, 1H),
1.59–1.51 (m, 1H), 1.28–1.22 (m, 1H), 1.25 (br s, 2H); 13C-NMR
(75 MHz, CDCl3): δC = 152.16 (Cq), 151.25 (+), 123.68 (+), 78.37
(+), 65.19 (+), 42.33 (−), 34.78 (−), 34.12 (+), 22.68 (+); IR (ATR):
ν˜ (cm−1) = 3356 (br), 3127, 2949, 1636, 1567, 1508, 1482, 1427,
1377, 1318, 1180, 1103, 1027, 980, 955, 849, 723, 646, 610; MS
(ESI): m/z (%) = 181.0 (7) [MH+], 222.0 (100) [MH+MeCN];
HRMS (ESI): calcd for C9H13N2O2 [MH
+] 181.0972, found
181.0969.
Preparation of (1S,3R,5S,6S)-ethyl 3-(hydroxymethyl)-2-oxabi-
cyclo[3.1.0]hexane-6-carboxylate (14). To a stirred ice-cooled
solution of 13 (2.45 g, 11.4 mmol) in anhydrous THF (45 mL)
under a nitrogen atmosphere, a suspension of LAH (260 mg,
6.87 mmol, 0.6 equiv.) in anhydrous THF (5 mL) was added
dropwise within 10 min. The reaction mixture was stirred for
45 min at 0 °C. After dropwise addition of water (260 µL) the
mixture was stirred for another 30 min. Then a 15% aqueous
NaOH solution (260 µL) was added, followed by water (780 µL).
The mixture was warmed to room temperature, treated
with MgSO4 and filtered through a Celite pad. The solvent was
evaporated under reduced pressure. The crude product was
Organic & Biomolecular Chemistry Paper
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purified by chromatography (PE–EtOAc 1 : 1) to obtain com-
pound 14 (1.85 g, 9.94 mmol, 87%) as a colorless oil.
Rf = 0.34 (PE–EtOAc 1 : 1), 0.49 (EtOAc); [α]
20
D = +63.7 (DCM,
c = 1.0); 1H-NMR (300 MHz, CDCl3): δH = 4.60–4.50 (m, 1H),
4.18 (d, J = 5.9 Hz, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.58 (ddd, J =
11.9, 6.0, 3.2 Hz, 1H), 3.41–3.31 (m, 1H), 2.37 (ddd, J = 13.1,
8.8, 7.0 Hz, 1H), 2.26–2.11 (m, 1H), 2.14 (br s, 1H), 1.81 (ddd,
J = 13.1, 7.7, 1.1 Hz, 1H), 1.72 (dd, J = 3.8, 0.8 Hz, 1H), 1.22 (t,
J = 7.1 Hz, 3H); 13C-NMR (75 MHz, CDCl3): δC = 170.50 (Cq),
87.00 (+), 67.37 (+), 64.91 (−), 60.59 (−), 33.39 (+), 30.31 (−),
27.56 (+), 14.33 (+); IR (ATR): ν˜ (cm−1) = 3460 (br), 2978, 2939,
2880, 1713, 1454, 1407, 1386, 1309, 1269, 1175, 1111, 1074,
1048, 980, 878, 851, 808, 712; MS (ESI): m/z (%) = 186.9 (40)
[MH+], 228.0 (100) [MH+MeCN], 373.1 (40) [2MH+], 390.0 (30)
[2MNH4
+]; HRMS (ESI): calcd for C9H15O4 [MH
+] 187.0965,
found 187.0966.
Preparation of (1S,3R,5S,6S)-ethyl 3-formyl-2-oxabicyclo-
[3.1.0]hexane-6-carboxylate (15). Dess–Martin periodinane
(4.24 g, 10.0 mmol, 1.05 equiv.) was added to a solution of
alcohol 14 (1.77 g, 9.52 mmol) in DCM (95 mL) at room temp-
erature and stirred for 1 h. After completion the reaction was
quenched with a mixture of saturated aqueous Na2S2O3 solu-
tion (50 mL) and saturated aqueous NaHCO3 solution (50 mL).
The mixture was stirred for 15 min; afterwards the organic
layer was separated and the aqueous layer was extracted with
DCM (2 × 50 mL). The combined organic layers were washed
with brine (1 × 50 mL), dried over MgSO4 and evaporated
in vacuo. The crude product was purified by chromatography
(PE–EtOAc 1 : 1) to give compound 15 (1.54 mg, 8.37 mmol,
88%) as a yellowish oil.
Rf = 0.31 (PE–EtOAc 1 : 1); [α]
20
D = +44.8 (DCM, c = 0.5);
1H-NMR (300 MHz, CDCl3): δH = 9.59 (s, 1H), 4.64 (dd, J = 10.6,
3.8 Hz, 1H), 4.34 (dd, J = 5.7, 0.8 Hz, 1H), 4.08 (q, J = 7.1 Hz,
2H), 2.51 (ddd, J = 13.4, 10.6, 5.7 Hz, 1H), 2.36 (dd, J = 13.3,
3.9 Hz, 1H), 2.20 (td, J = 5.5, 3.9 Hz, 1H), 1.46 (dd, J = 3.8,
1.0 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H), 1.26–1.19 (m, 1H); 13C-NMR
(75 MHz, CDCl3): δC = 203.36 (+), 170.20 (Cq), 85.29 (+), 67.22
(+), 60.85 (−), 30.26 (−), 27.54 (+), 25.21 (+), 14.31 (+); IR (ATR):
ν˜ (cm−1) = 3435 (br), 2984, 1712, 1451, 1411, 1385, 1323, 1298,
1273, 1177, 1107, 1051, 1035, 976, 926, 870, 849, 796, 749, 702;
MS (CI): m/z (%) = 185.0 (15) [MH+], 202.1 (100) [MNH4
+];
HRMS (ESI): calcd for C9H13O4 [MH
+] 185.0808, found
185.0808.
Preparation of (1S,3R,5S,6S)-ethyl 3-(4-tosyl-4,5-dihydrooxa-
zol-5-yl)-2-oxabicyclo[3.1.0]hexane-6-carboxylate (16). Finely
powdered NaCN (70 mg, 1.42 mmol, 0.18 equiv.) was added in
one portion to a stirred solution of TosMIC (1.70 g, 8.70 mmol,
1.1 equiv.) and aldehyde 15 (1.46 g, 7.91 mmol) in anhydrous
EtOH (80 mL) at room temperature under a nitrogen atmos-
phere. After 1 h, the solvent was evaporated under reduced
pressure. The residue was dissolved in CHCl3 (100 mL)
and washed with a saturated aqueous NaHCO3 solution
(1 × 100 mL). The aqueous layer was extracted with CHCl3
(1 × 40 mL) and the combined organic layers were dried
over MgSO4, filtered and concentrated in vacuo. Purification
by column chromatography (PE–EtOAc 1 : 1) aﬀorded a 2 : 1
diastereomeric mixture of compound 16 (2.10 g, 5.54 mmol,
70%) as a yellowish foam.
Major: Rf = 0.29 (PE–EtOAc 1 : 1);
1H-NMR (400 MHz,
CDCl3): δH = 7.80 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 8.2 Hz, 2H),
7.01 (s, 1H), 4.91 (dd, J = 5.8, 4.4 Hz, 1H), 4.86 (dd, J = 5.9,
1.7 Hz, 1H), 4.60–4.52 (m, 1H), 4.17 (d, J = 6.0 Hz, 1H), 4.09 (q,
J = 7.1 Hz, 2H), 2.51–2.41 (m, 1H), 2.44 (s, 3H), 2.27–2.20 (m,
1H), 1.88 (ddd, J = 13.6, 8.2, 1.2 Hz, 1H), 1.73 (d, J = 3.8, 1H),
1.23 (t, J = 7.1, 3H); 13C-NMR (75 MHz, CDCl3): δC = 169.87
(Cq), 159.32 (+), 145.83 (Cq), 132.87 (Cq), 129.97 (+), 129.63 (+),
86.60 (+), 85.71 (+), 79.54 (+), 67.06 (+), 60.71 (−), 33.52 (+),
30.01 (−), 26.70 (+), 21.82 (+), 14.29 (+).
Minor: Rf = 0.29 (PE–EtOAc 1 : 1);
1H-NMR (400 MHz,
CDCl3): δH = 7.79 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.3 Hz, 2H),
7.00 (s, 1H), 4.99 (dd, J = 6.4, 1.7 Hz, 1H), 4.88–4.81 (m, 1H),
4.63–4.55 (m, 1H), 4.15 (d, J = 6.0 Hz, 1H), 4.07 (q, J = 7.1 Hz,
2H), 2.57–2.49 (m, 1H), 2.44 (s, 3H), 2.27–2.20 (m, 1H), 2.12
(ddd, J = 13.4, 8.2, 1.0 Hz, 1H), 1.73, (d, J = 3.8, 1H), 1.21 (t, J =
7.1, 3H); 13C-NMR (75 MHz, CDCl3): δC = 170.04 (Cq), 159.15
(+), 145.79 (Cq), 133.02 (Cq), 129.97 (+), 129.53 (+), 87.27 (+),
86.65 (+), 68.76 (+), 67.33 (+), 60.64 (−), 33.15 (+), 30.58 (−),
27.11 (+), 21.82 (+), 14.29 (+).
Data for the isomeric mixture: IR (ATR): ν˜ (cm−1) = 2978,
2936, 1716, 1618, 1453, 1408, 1387, 1306, 1177, 1149, 1108,
1086, 1075, 975, 934, 852, 813, 707, 668; Elemental analysis
calcd (%) for C16H21NO6S·1.2H2O: C 53.91, H 5.88, N 3.49, S
8.00, found C 53.83, H 5.93, N 3.34, S 7.92.
Preparation of (1S,3R,5S,6S)-ethyl 3-((tert-butyldimethyl-silyl-
oxy)methyl)-2-oxabicyclo[3.1.0]hexane-6-carboxylate (18). To a
stirred solution of alcohol 14 (2.53 g, 13.6 mmol) in DCM
(45 mL) under a nitrogen atmosphere, anhydrous NEt3
(2.8 mL, 20 mmol, 1.5 equiv.), TBSCl (2.48 g, 16.5 mmol,
1.2 equiv.) and DMAP (83 mg, 0.68 mmol, 0.05 equiv.) were
added successively. The reaction mixture was stirred for 18 h at
room temperature and then quenched with a saturated
aqueous NH4Cl solution (40 mL). The layers were separated
and the aqueous layer was extracted with DCM (2 × 20 mL).
The combined organic phases were dried over MgSO4, filtered
and concentrated in vacuo. Purification by column chromato-
graphy (PE–EtOAc 5 : 1) aﬀorded compound 18 (3.88 g,
12.9 mmol, 95%) as a colorless oil.
Rf = 0.52 (PE–EtOAc 5 : 1); [α]
20
D = +35.0 (DCM, c = 1.0);
1H-NMR (300 MHz, CDCl3): δH = 4.48 (ddt, J = 9.1, 7.0, 4.1 Hz,
1H), 4.13 (d, J = 5.9 Hz, 1H), 4.06 (q, J = 7.1 Hz, 2H), 3.54 (dd,
J = 11.0, 4.0 Hz, 1H), 3.45 (dd, J = 11.0, 4.2 Hz, 1H), 2.33 (ddd,
J = 13.0, 9.2, 6.9 Hz, 1H), 2.21–2.11 (m, 1H), 1.91 (ddd, J = 13.0,
6.9, 0.8 Hz, 1H), 1.87 (dd, J = 3.9, 0.9 Hz, 1H), 1.21 (t, J =
7.1 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 13C-NMR
(75 MHz, CDCl3): δC = 170.74 (+), 86.16 (+), 67.32 (+), 65.31 (−),
60.22 (−), 32.22 (+), 30.13 (−), 27.42 (+), 25.94 (+), 18.38 (Cq),
14.23 (+), −5.35 (+), −5.43 (+); IR (ATR): ν˜ (cm−1) = 2955, 2931,
2858, 1720, 1463, 1408, 1309, 1256, 1176, 1112, 1096, 1054,
979, 839, 778; MS (ESI): m/z (%) = 301.0 (100) [MH+]; HRMS
(EI): calcd for C15H28SiO4 [M
+˙] 300.1757, found 300.1760.
Preparation of ((1S,3R,5S,6R)-3-((tert-butyldimethylsilyloxy)-
methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)-methanol (19). To a
Paper Organic & Biomolecular Chemistry
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stirred ice-cooled solution of 18 (3.88 g, 12.9 mmol) in anhy-
drous THF (50 mL) under a nitrogen atmosphere, a suspension
of LAH (412 mg, 10.9 mmol, 0.84 equiv.) in anhydrous THF
(5 mL) was added dropwise within 10 min. The reaction
mixture was stirred for 45 min at 0 °C. After dropwise addition
of water (0.41 mL) the mixture was stirred for another 30 min.
Then a 15% aqueous NaOH solution (0.41 mL) was added, fol-
lowed by water (1.24 mL). The mixture was warmed to room
temperature, treated with MgSO4 and filtered through a Celite
pad. The solvent was evaporated under reduced pressure.
The crude product was purified by column chromatography
(PE–EtOAc 3 : 1 then 1 : 1) to obtain compound 19 (3.17 g,
12.3 mmol, 95%) as a colorless oil.
Rf = 0.30 (PE–EtOAc 1 : 1); [α]
20
D = +44.6 (DCM, c = 1.0);
1H-NMR (300 MHz, CDCl3): δH = 4.43 (tt, J = 7.9, 4.9 Hz, 1H),
3.73 (dd, J = 6.3, 1.1 Hz, 1H), 3.46 (d, J = 4.9 Hz, 2H), 3.37–3.21
(m, 2H), 2.23 (ddd, J = 12.8, 8.3, 7.2 Hz, 1H), 2.21 (br s, 1H),
1.68 (ddd, J = 12.8, 7.6, 1.5 Hz, 1H), 1.51–1.43 (m, 1H),
1.21–1.13 (m, 1H), 0.85 (s, 9H), 0.01 (s, 6H); 13C-NMR (75 MHz,
CDCl3): δC = 87.94 (+), 66.01 (−), 64.33 (+), 62.32 (−), 34.78 (+),
31.54 (−), 26.01 (+), 21.98 (+), 18.45 (Cq), −5.25 (+), −5.27 (+);
IR (ATR): ν˜ (cm−1) = 3386 (br), 2953, 2929, 2858, 1463, 1410,
1254, 1130, 1095, 1023, 837, 777, 669; MS (ESI): m/z (%) =
241.0 (78) [MH+ΔH2O], 259.0 (55) [MH+], 276.1 (20) [MNH4+],
300.0 (100) [MH+MeCN], 481.2 (35) [2MH+Δ2H2O], 499.2 (85)
[2MH+ΔH2O], 517.2 (50) [2MH+]; HRMS (ESI): calcd for
C13H27O3Si [MH
+] 259.1724, found 259.1731.
Preparation of (((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabi-
cyclo[3.1.0]hexan-3-yl)methoxy)(tert-butyl)-dimethylsilane (20).
To a solution of alcohol 19 (1.00 g, 3.87 mmol) in anhydrous
DMF (25 mL), NaH (309 mg, 60 wt% in mineral oil,
7.74 mmol, 2.0 equiv.) was added in one portion at 0 °C under
a nitrogen atmosphere. The resulting suspension was stirred at
0 °C for 10 min, and then benzyl bromide (919 µL, 7.74 mmol,
2.0 equiv.) was added dropwise at 0 °C. The mixture was
allowed to warm to room temperature and stirred for 2 h.
MeOH (5 mL) was added carefully to quench the reaction. The
solvent was evaporated under reduced pressure. The residue
was diluted in DCM and washed with a saturated aqueous
NH4Cl solution (20 mL). The aqueous phase was extracted with
DCM (3 × 20 mL). The organic layers were combined, dried
over MgSO4 and concentrated in vacuo. The resulting residue
was purified by column chromatography (PE–EtOAc 9 : 1) to
obtain compound 20 (1.14 g, 3.28 mmol, 85%) as a colorless
oil.
Rf = 0.22 (PE–EtOAc 9 : 1), 0.53 (PE–EtOAc 3 : 1); [α]
20
D = +22.5
(DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): δH = 7.38–7.22
(m, 5H), 4.46 (ddd, J = 9.8, 8.1, 4.9 Hz, 3H), 3.75 (dd, J = 6.2,
1.1 Hz, 1H), 3.50 (d, J = 5.0 Hz, 2H), 3.35 (dd, J = 10.6, 6.6 Hz,
1H), 3.09 (dd, J = 10.6, 7.6 Hz, 1H), 2.27 (ddd, J = 12.8, 8.3, 7.2
Hz, 1H), 1.74 (ddd, J = 12.8, 7.5, 1.5 Hz, 1H), 1.61–1.45
(m, 1H), 1.23 (dddd, J = 7.7, 6.7, 4.0, 1.2 Hz, 1H), 0.90 (s, J = 2.9
Hz, 9H), 0.06 (d, J = 1.0 Hz, 6H); 13C-NMR (75 MHz, CDCl3): δC
= 138.50 (Cq), 128.49 (+), 127.75 (+), 127.68 (+), 87.80 (+), 72.50
(−), 69.61 (−), 66.20 (−), 64.62 (+), 31.99 (+), 31.66 (−), 26.10
(+), 22.45 (+), 18.54 (Cq), −5.18 (+); IR (ATR): ν˜ (cm−1) = 3038,
2932, 2858, 1461, 1380, 1254, 1182, 1132, 1091, 1009, 840,
778, 738, 697; MS (ESI): m/z (%) = 241.1 (100) [M+ΔC7H7O],
349.1 (15) [MH+], 366.1 (65) [MNH4
+], 714.5 (20) [2MNH4
+];
HRMS (ESI): calcd for C20H33O3Si [MH
+] 349.2193, found
349.2197.
Preparation of ((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicy-
clo[3.1.0]hexan-3-yl)methanol (21). To a solution of compound
20 (3.03 mg, 8.69 mmol) in anhydrous THF (60 mL) a solution
of TBAF·3H2O (4.11 mg, 13.0 mmol, 1.5 equiv.) in anhydrous
THF (30 mL) was added and stirred for 13 h at room tempera-
ture. After evaporating the solvent the crude product was puri-
fied by column chromatography (EtOAc) to give 21 (1.94 mg,
8.28 mmol, 95%) as a colorless oil.
Rf = 0.42 (EtOAc); [α]
20
D = +47.2 (DCM, c = 1.0);
1H-NMR
(300 MHz, CDCl3): δH = 7.39–7.23 (m, 5H), 4.59–4.49 (m, 1H),
4.48 (d, J = 2.2 Hz, 2H), 3.78 (dd, J = 6.2, 1.1 Hz, 1H), 3.56 (ddd,
J = 11.4, 5.4, 3.2 Hz, 1H), 3.42–3.31 (m, 1H), 3.26 (dd, J = 10.5,
7.0 Hz, 1H), 3.16 (dd, J = 10.5, 7.1 Hz, 1H), 2.26 (ddd, J = 12.8,
8.1, 7.3 Hz, 1H), 2.07 (br s, 1H), 1.69 (ddd, J = 12.8, 8.0, 1.6 Hz,
1H), 1.55 (dddd, J = 7.6, 6.0, 4.0, 1.6 Hz, 1H), 1.20 (tdd, J = 7.1,
4.0, 1.2 Hz, 1H); 13C-NMR (75 MHz, CDCl3): δC = 138.35 (Cq),
128.51 (+), 127.78 (+), 127.74 (+), 88.08 (+), 72.67 (−), 69.47 (−),
65.36 (−), 64.71 (+), 32.57 (+), 31.17 (−), 22.51 (+); IR (ATR):
ν˜ (cm−1) = 3421 (br), 3027, 2924, 2862, 1497, 1454, 1414, 1360,
1180, 1087, 1071, 1028, 987, 844, 810, 739, 698, 614; MS (ESI):
m/z (%) = 235.0 (5) [MH+], 469.0 (25) [2MH+], 486.1 (75)
[2MH4
+], 491.1 (100) [2MNa+]; HRMS (ESI): calcd for
C14H18NaO3 [MNa
+] 257.1148, found 257.1153.
Preparation of (1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabicy-
clo[3.1.0]hexane-3-carbaldehyde (22). To a stirred solution of
alcohol 21 (4.35 g, 18.6 mmol) in DCM (150 mL) was added in
one portion Dess–Martin periodinane (8.66 g, 20.4 mmol, 1.1
equiv.) at room temperature. After 2 h, a saturated aqueous
NaHCO3 (60 mL) and a saturated aqueous Na2S2O3 (60 mL)
were added. The mixture was stirred for another 15 min. After
completion the reaction was quenched with a mixture of satu-
rated aqueous Na2S2O3 solution (60 mL) and saturated
aqueous NaHCO3 solution (60 mL). The mixture was stirred for
15 min, then the organic layer was separated and the aqueous
layer was extracted with DCM (2 × 50 mL). The combined
organic layers were washed with brine (1 × 50 mL), dried over
MgSO4 and evaporated in vacuo. Purification by column
chromatography (PE–EtOAc 1 : 1) aﬀorded compound 22
(3.87 g, 16.7 mmol, 90%) as a colorless oil.
Rf = 0.31 (PE–EtOAc 1 : 1); [α]
20
D = +57.5 (DCM, c = 1.0);
1H-NMR (300 MHz, CDCl3): δH = 9.57 (d, J = 0.8 Hz, 1H),
7.39–7.21 (m, 5H), 4.58 (ddd, J = 10.2, 3.9, 0.7 Hz, 1H), 4.47 (d,
J = 1.1 Hz, 2H), 3.95 (dd, J = 5.9, 1.3 Hz, 1H), 3.30 (dd, J = 10.5,
6.7 Hz, 1H), 3.17 (dd, J = 10.5, 7.1 Hz, 1H), 2.40 (ddd, J = 13.0,
10.3, 5.9 Hz, 1H), 2.26 (ddd, J = 13.0, 4.0, 0.6 Hz, 1H), 1.53
(tdd, J = 5.8, 4.0, 0.6 Hz, 1H), 0.97 (tdd, J = 6.9, 3.9, 1.3 Hz, 1H);
13C-NMR (75 MHz, CDCl3): δC = 204.38 (+), 138.19 (Cq), 128.54
(+), 127.81 (+), 127.77 (+), 86.02 (+), 72.77 (−), 69.06 (−), 64.86
(+), 31.08 (−), 25.84 (+), 20.30 (+); IR (ATR): ν˜ (cm−1) = 3031,
2942, 2860, 1730, 1497, 1455, 1422, 1362, 1091, 1076, 1030,
988, 738, 699; MS (EI): m/z (%) = 91.1 (100) [C7H7
+], 231.1 (<1)
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[M˙ΔH+]; HRMS (ESI): calcd for C14H20NO3 [MNH4+] 250.1438,
found 250.1439.
Preparation of 5-((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabi-
cyclo[3.1.0]hexan-3-yl)-4-tosyl-4,5-dihydro-oxazole (23). Finely
powdered NaCN (28 mg, 0.57 mmol, 0.22 equiv.) was added in
one portion to a stirred solution of TosMIC (555 mg,
2.84 mmol, 1.1 equiv.) and aldehyde 22 (600 mg, 2.58 mmol)
in anhydrous EtOH (25 mL) at room temperature under a
nitrogen atmosphere. The reaction mixture was stirred for 2 h.
The solvent was evaporated under reduced pressure. The
residue was dissolved in CHCl3 (30 mL) and washed with a
saturated aqueous NaHCO3 solution (30 mL). The aqueous
layer was extracted with CHCl3 (2 × 15 mL) and the combined
organic layers were dried over MgSO4, filtered and con-
centrated in vacuo. Purification by column chromatography
(PE–EtOAc 1 : 1) aﬀorded a 3 : 2 diastereomeric mixture of com-
pound 23 (854 mg, 2.00 mmol, 77%) as yellowish foam.
Major: Rf = 0.41 (PE–EtOAc 1 : 1);
1H-NMR (300 MHz,
CDCl3): δH = 7.81 (d, J = 8.3 Hz, 2H), 7.39–7.33 (m, 2H),
7.34–7.20 (m, 5H), 7.00–6.96 (m, 1H), 4.94–4.91 (m, 1H),
4.92–4.89 (m, 1H), 4.62–4.52 (m, 1H), 4.51–4.45 (m, 2H), 3.79
(dd, J = 6.2, 0.9 Hz, 1H), 3.31 (dd, J = 10.5, 6.5 Hz, 1H), 3.11
(dd, J = 10.5, 7.3 Hz, 1H), 2.44 (s, 3H), 2.40–2.20 (m, 1H), 1.81
(ddd, J = 13.3, 8.8, 1.3 Hz, 1H), 1.65–1.53 (m, 1H), 1.30–1.18
(m, 1H); 13C-NMR (75 MHz, CDCl3): δC = 159.28 (+), 145.62
(Cq), 138.15 (Cq), 133.09 (Cq), 129.89 (+), 129.60 (+), 128.47 (+),
127.75 (+), 127.71 (+), 86.80 (+), 86.36 (+), 79.63 (+), 72.70 (−),
69.00 (−), 64.69 (+), 33.03 (+), 30.85 (−), 22.12 (+), 21.79 (+).
Minor: Rf = 0.41 (PE–EtOAc 1 : 1);
1H-NMR (300 MHz,
CDCl3): δH = 7.80 (d, J = 8.3 Hz, 2H), 7.39–7.33 (m, 2H),
7.34–7.20 (m, 5H), 7.00–6.96 (m, 1H), 4.98 (dd, J = 6.2, 1.7 Hz,
1H), 4.84 (dd, J = 6.2, 3.4 Hz, 1H), 4.58–4.50 (m, 1H), 4.47–4.42
(m, 2H), 3.76 (dd, J = 6.3, 0.8 Hz, 1H), 3.26 (dd, J = 10.5, 6.8 Hz,
1H), 3.14 (dd, J = 10.5, 7.2 Hz, 1H), 2.44 (s, 3H), 2.43–2.33 (m,
1H), 2.01 (ddd, J = 13.0, 8.4, 1.6 Hz, 1H), 1.65–1.53 (m, 1H),
1.30–1.18 (m, 1H); 13C-NMR (75 MHz, CDCl3): δC = 159.35 (+),
145.62 (Cq), 138.19 (Cq), 133.09 (Cq), 129.89 (+), 129.52 (+),
128.45 (+), 127.75 (+), 127.71 (+), 87.66 (+), 87.31 (+), 79.13 (+),
72.63 (−), 69.04 (−), 64.92 (+), 32.83 (+), 31.19 (−), 22.12 (+),
21.79 (+).
Data for the isomeric mixture: IR (ATR): ν˜ (cm−1) = 3033,
2948, 2861, 1616, 1597, 1486, 1455, 1362, 1319, 1304, 1292,
1148, 1108, 1086, 1071, 1028, 939, 848, 813, 739, 700, 664, 651,
587, 533.
Preparation of 5-((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-oxabi-
cyclo[3.1.0]hexan-3-yl)-1H-imidazole (24a) and 5-((1S,3S ,5S,6R)-
6-(benzyloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole
(24b). In a sealable pressure tube, oxazoline 23 (1.70 g,
3.98 mmol) and a saturated solution of NH3 in anhydrous
MeOH (40 mL, 70 equiv.) were heated at 95 °C for 16 h.
Within this time the solution turned red. After cooling,
the solvent was removed under reduced pressure. The
residue was purified by column chromatography (DCM–
saturated NH3 in MeOH 9 : 1) to give a 5 : 1 epimeric mixture
of compounds 24a and 24b (726 mg, 2.69 mmol, 68%) as a
colorless oil.
24a: Rf = 0.22 (DCM–saturated NH3 in MeOH 9 : 1);
1H-NMR
(300 MHz, CDCl3): δH = 8.28 (br s, 1H), 7.48 (s, 1H), 7.38–7.22
(m, 5H), 6.83 (s, 1H), 5.42 (t, J = 7.5 Hz, 1H), 4.47 (d, J = 1.7 Hz,
2H), 3.86 (dd, J = 6.2, 1.2 Hz, 1H), 3.29–3.15 (m, 2H), 2.64–2.51
(m, 1H), 2.15 (ddd, J = 12.8, 7.0, 1.4 Hz, 1H), 1.66–1.57 (m,
1H), 1.45–1.34 (m, 1H); 13C-NMR (75 MHz, CDCl3): δC = 139.57
(Cq), 138.27 (Cq), 135.36 (+), 128.54 (+), 127.87 (+), 127.80 (+),
116.10 (+), 81.53 (+), 72.69 (−), 69.71 (−), 64.45 (+), 35.21 (−),
30.89 (+), 22.67 (+).
24b: Rf = 0.22 (DCM–saturated NH3 in MeOH 9 : 1);
1H-NMR
(300 MHz, CDCl3): δH = 8.28 (br s, 1H), 7.55 (s, 1H), 7.38–7.22
(m, 5H), 6.90 (s, 1H), 4.76 (t, J = 8.2 Hz, 1H), 4.50 (d, J = 2.6 Hz,
2H), 3.90–3.78 (m, 1H), 3.42–3.31 (m, 1H), 3.23–3.11 (m, 1H),
2.38–2.23 (m, 2H), 1.59–1.48 (m, 1H), 1.19–1.05 (m, 1H);
13C-NMR (75 MHz, CDCl3): δC = 138.22 (Cq), 137.81 (Cq),
135.62 (+), 128.54 (+), 127.86 (+), 127.80 (+), 115.90 (+), 74.14
(+), 72.72 (−), 69.90 (−), 62.56 (+), 34.54 (−), 21.40 (+),
20.80 (+).
Data for the isomeric mixture: IR (ATR): ν˜ (cm−1) = 3090
(br), 2936, 2858, 1716, 1670, 1496, 1453, 1362, 1313, 1273,
1087, 1071, 1027, 839, 738, 698, 626; MS (ESI): m/z (%) = 271.0
(100) [MH+], 312.1 (30) [MH+MeCN], 541.2 (40) [2MH+]; HRMS
(ESI): calcd for C16H19N2O2 [MH
+] 271.1441, found 271.1446.
Preparation of ethyl 5-((1S,3R,5S,6R)-6-(benzyloxymethyl)-2-
oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole-1-carboxylate (25a)
and ethyl 5-((1S,3S,5S,6R)-6-(benzyloxymethyl)-2-oxabicyclo-
[3.1.0]hexan-3-yl)-1H-imidazole-1-carboxylate (25b). A solution
of a 3 : 1 epimeric mixture of imidazole 24a and 24b (1.10 g,
4.06 mmol), ethyl chloroformate (733 µL, 7.72 mmol,
1.9 equiv.), anhydrous pyridine (623 µL, 7.72 mmol, 1.9 equiv.)
and DMAP (79 mg, 0.65 mmol, 0.16 equiv.) in benzene (80 mL)
was stirred for 10 min at 50 °C. After the addition of water
(5 mL), the solvent was evaporated. A saturated aqueous NH4Cl
solution (50 mL) was added and extracted with DCM (3 ×
25 mL). The extract was washed with brine, dried over MgSO4,
filtered and concentrated in vacuo. The residual oil was puri-
fied by column chromatography (PE–EtOAc 1 : 1) to give a 3 : 1
epimeric mixture of compounds 25a and 25b (1.01 g,
2.95 mmol, 73%) as a colorless oil.
25a: Rf = 0.26 (PE–EtOAc 1 : 1);
1H-NMR (300 MHz, CDCl3):
δH = 8.06 (d, J = 1.3 Hz, 1H), 7.37–7.27 (m, 5H), 7.28 (t, J =
1.2 Hz, 1H), 5.38 (ddd, J = 8.4, 6.7, 0.9 Hz, 1H), 4.48 (d, J =
3.8 Hz, 2H), 4.45 (q, J = 7.1 Hz, 2H), 3.88 (dd, J = 6.1, 1.2 Hz,
1H), 3.33 (dd, J = 10.5, 6.7 Hz, 1H), 3.13 (dd, J = 10.6, 7.4 Hz,
1H), 2.61 (ddd, J = 12.8, 8.6, 6.9 Hz, 1H), 2.15 (ddd, J = 12.8,
6.7, 1.4 Hz, 1H), 1.67–1.57 (m, 1H), 1.47–1.39 (m, 1H), 1.42 (t,
J = 7.1 Hz, 3H); 13C-NMR (75 MHz, CDCl3): δC = 148.63 (Cq),
145.81 (Cq), 138.32 (Cq), 137.17 (+), 128.41 (+), 127.70 (+),
127.26 (+), 113.26 (+), 81.75 (+), 72.52 (−), 69.50 (−), 64.68 (+),
64.45 (−), 43.88 (−), 30.63 (+), 22.66 (+), 14.21 (+).
25b: Rf = 0.24 (PE–EtOAc 1 : 1), 0.54 (EtOAc);
1H-NMR
(300 MHz, CDCl3): δH = 8.07 (d, J = 1.3 Hz, 1H), 7.35–7.26 (m,
5H), 7.33–7.31 (m, 1H), 4.72 (dd, J = 8.8, 7.4 Hz, 1H), 4.49 (d,
J = 3.1 Hz, 2H), 4.43 (q, J = 7.1 Hz, 2H), 3.91 (dd, J = 5.5,
1.6 Hz, 1H), 3.38 (dd, J = 10.5, 6.2 Hz, 1H), 3.13 (dd, J = 10.5,
7.5 Hz, 2H), 2.35 (dd, J = 12.3, 7.3 Hz, 1H), 2.24 (ddd, J = 12.4,
Paper Organic & Biomolecular Chemistry
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9.0, 5.0 Hz, 1H), 1.59–1.50 (m, 2H), 1.40 (t, J = 7.1 Hz, 3H);
13C-NMR (75 MHz, CDCl3): δC = 148.58 (Cq), 143.45 (Cq),
138.34 (Cq), 137.26 (+), 128.44 (+), 127.72 (+), 127.67 (+), 113.85
(+), 74.88 (+), 72.58 (−), 69.71 (−), 64.49 (−), 62.91 (+), 34.52
(−), 22.14 (+), 20.86 (+), 14.21 (+).
Data for isomeric mixture: IR (ATR): ν˜ (cm−1) = 3032, 2937,
2859, 1759, 1482, 1454, 1409, 1388, 1336, 1252, 1207, 1093,
1069, 1019, 843, 769, 740, 699, 607; MS (ESI): m/z (%) = 342.9
(100) [MH+]; HRMS (ESI): calcd for C19H23N2O4 [MH
+]
343.1652, found 343.1656.
Preparation of ethyl 5-((1S,3R,5S,6R)-6-(hydroxymethyl)-2-
oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole-1-carboxylate (26a)
and ethyl 5-((1S,3S,5S,6R)-6-(hydroxymethyl)-2-oxabicyclo-
[3.1.0]hexan-3-yl)-1H-imidazole-1-carboxylate (26b). A 3 : 1 epi-
meric mixture of compounds 25a and 25b (134 mg,
0.39 mmol), Pd(OH)2–C (20%, 95 mg) and cyclohexene
(1.6 mL, 16 mmol, 40 equiv.) in anhydrous EtOH (15 mL) was
refluxed for 1 h. After filtration through a Celite pad the
solvent was evaporated. The residue was purified by column
chromatography (EtOAc, then EtOAc–MeOH 19 : 1) to aﬀord a
3 : 1 epimeric mixture of alcohol 26a and 26b (72 mg,
0.29 mmol, 73%) as a colorless foam. Separation of the
epimers by iterated chromatography.
26a: Rf = 0.38 (EtOAc–MeOH 19 : 1); [α]
20
D = −4.6 (DCM, c =
1.0); 1H-NMR (300 MHz, CDCl3): δH = 8.06 (d, J = 1.3 Hz, 1H),
7.29 (m, 1H), 5.38 (ddd, J = 8.5, 6.6, 0.9 Hz, 1H), 4.45 (q, J =
7.1 Hz, 2H), 3.90 (dd, J = 6.2, 1.3 Hz, 1H), 3.40 (dd, J = 11.6,
7.4 Hz, 1H), 3.33 (dd, J = 11.6, 7.3 Hz, 1H), 2.61 (ddd, J = 12.8,
8.6, 6.9 Hz, 1H), 2.16 (ddd, J = 12.8, 6.7, 1.5 Hz, 1H), 1.75 (br s,
1H), 1.62 (tdd, J = 6.8, 4.0, 1.5 Hz, 1H), 1.50–1.43 (m, 1H), 1.42
(t, J = 7.1 Hz, 3H); 13C-NMR (75 MHz, CDCl3): δC = 148.69 (Cq),
145.65 (Cq), 137.31 (+), 113.54 (+), 81.81 (+), 64.60 (−), 64.51
(+), 62.61 (−), 34.83 (−), 33.45 (+), 22.44 (+), 14.30 (+); IR (ATR):
ν˜ (cm−1) = 3373 (br), 2982, 2943, 2876, 1758, 1489, 1409, 1336,
1253, 1176, 1103, 1068, 1018, 847, 768, 606; MS (ESI): m/z (%)
= 252.9 (40) [MH+], 294.0 (15) [MH+MeCN], 505.1 (100) [2MH+];
HRMS (ESI): calcd for C12H17N2O4 [MH
+] 253.1183, found
253.1190.
26b: Rf = 0.36 (EtOAc–MeOH 19 : 1); [α]
20
D = +10.5 (DCM, c =
1.0); 1H-NMR (300 MHz, CDCl3): δH = 8.05 (d, J = 1.2 Hz, 1H),
7.32–7.29 (m, 1H), 4.70 (dd, J = 8.6, 7.5 Hz, 1H), 4.42 (q, J =
7.1 Hz, 2H), 3.91 (dd, J = 5.5, 1.6 Hz, 1H), 3.41 (dd, J = 11.5,
6.8 Hz, 1H), 3.32 (dd, J = 11.5, 7.1 Hz, 1H), 2.32 (dd, J = 12.4,
7.2 Hz, 1H), 2.21 (ddd, J = 12.4, 9.0, 5.0 Hz, 1H), 1.58–1.47 (m,
2H), 1.38 (t, J = 7.1 Hz, 3H); 13C-NMR (75 MHz, CDCl3): δC =
148.66 (Cq), 143.43 (Cq), 137.38 (+), 113.98 (+), 75.10 (+), 64.64
(−), 62.86 (−), 62.42 (+), 34.59 (−), 24.90 (+), 20.54 (+), 14.30
(+); IR (ATR): ν˜ (cm−1) = 3349 (br), 2939, 2869, 1760, 1487,
1409, 1342, 1254, 1123, 1018, 852, 768, 607; MS (ESI): m/z (%)
= 252.8 (100) [MH+], 505.1 (30) [2MH+]; HRMS (ESI): calcd for
C12H17N2O4 [MH
+] 253.1183, found 253.1188.
Preparation of ethyl 5-((1S,3R,5S,6R)-6-((1,3-dioxoisoindolin-
2-yl)methyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole-1-car-
boxylate (27a), ethyl 5-((2R,4S,5R)-5-(1,3-dioxoisoindolin-2-yl)-
4-vinyltetrahydrofuran-2-yl)-1H-imidazole-1-carboxylate (28a)
and ethyl 5-((2R,4S,5S)-5-(1,3-dioxoisoindolin-2-yl)-4-
vinyltetrahydrofuran-2-yl)-1H-imidazole-1-carboxylate (28b).
DIAD (211 mg, 0.98 mmol, 1.5 equiv.) was added to a solution
of PPh3 (257 mg, 0.98 mmol, 1.5 equiv.) in anhydrous THF
(7 mL) at room temperature under a nitrogen atmosphere.
After stirring for 10 min phthalimide (144 mg, 0.98 mmol,
1.5 equiv.) was added and stirred for another 10 min. After
addition of alcohol 26a (165 mg, 0.65 mmol) in THF the reac-
tion mixture was stirred overnight. The solvent was evaporated
under reduced pressure. The residue was purified by column
chromatography (PE–EtOAc 5 : 1 to EtOAc) to obtain 28a
(126 mg, 0.33 mmol, 51%), 28b (25 mg, 0.07 mmol, 10%) and
27a (72 mg, 0.19 mmol, 29%) as colorless oils.
28a: Rf = 0.37 (PE–EtOAc 1 : 1); [α]
20
D = −23.6 (DCM, c = 1.0);
1H-NMR (300 MHz, CDCl3): δH = 8.10 (d, J = 1.2 Hz, 1H), 7.85
(dd, J = 5.5, 3.0 Hz, 2H), 7.72 (dd, J = 5.5, 3.0 Hz, 2H), 7.40 (dd,
J = 1.3, 0.7 Hz, 1H), 5.93 (d, J = 7.5 Hz, 1H), 5.86 (ddd, J = 17.1,
10.3, 8.0 Hz, 1H), 5.50 (dd, J = 10.6, 4.9 Hz, 1H), 5.13 (dt, J =
17.1, 1.2 Hz, 1H), 5.10–5.04 (m, 1H), 4.44 (q, J = 7.1 Hz, 2H),
4.01–3.85 (m, 1H), 2.65 (ddd, J = 12.2, 7.2, 5.0 Hz, 1H), 2.24
(dt, J = 12.2, 11.3 Hz, 1H), 1.41 (t, J = 7.1 Hz, 3H); 13C-NMR
(75 MHz, CDCl3): δC = 167.92 (Cq), 148.63 (Cq), 143.33 (Cq),
137.37 (+), 136.39 (+), 134.37 (+), 132.02 (Cq), 123.60 (+), 117.58
(−), 114.40 (+), 85.06 (+), 76.33 (+), 64.59 (−), 46.68 (+), 39.34
(−), 14.27 (+); IR (ATR): ν˜ (cm−1) = 2985, 2927, 2853, 1760,
1716, 1468, 1410, 1367, 1332, 1252, 1210, 1084, 1019 977, 919,
891, 845, 769, 736, 721, 655, 611, 531; MS (ESI): m/z (%) =
381.9 (100) [MH+], 422.9 (45) [MH+MeCN], 763.2 (90) [2MH+];
HRMS (ESI): calcd for C20H20N3O5 [MH
+] 382.1375, found
382.1365.
28b: Rf = 0.33 (PE–EtOAc 1 : 1); [α]
20
D = +73.6 (DCM, c = 0.5);
1H-NMR (300 MHz, CDCl3): δH = 8.09 (d, J = 1.3 Hz, 1H), 7.83
(dd, J = 5.5, 3.0 Hz, 2H), 7.72 (dd, J = 5.5, 3.0 Hz, 2H),
7.61–7.53 (m, 1H), 6.21 (d, J = 8.6 Hz, 1H), 5.69 (ddd, J = 17.5,
10.2, 7.5 Hz, 1H), 5.20 (dt, J = 17.2, 1.3 Hz, 1H), 5.11–5.04 (m,
1H), 5.06–5.00 (m, 1H), 4.46 (q, J = 7.1 Hz, 2H), 3.56–3.41 (m,
1H), 2.93–2.77 (m, 1H), 2.51–2.40 (m, 1H), 1.42 (t, J = 7.1 Hz,
3H); 13C-NMR (75 MHz, CDCl3): δC = 167.77 (Cq), 148.78 (Cq),
143.44 (Cq), 136.78 (+), 134.30 (+), 133.84 (+), 131.98 (Cq),
123.61 (+), 118.82 (−), 114.31 (+), 82.69 (+), 77.63 (+), 64.53 (−),
47.93 (+), 36.93 (−), 14.33 (+); IR (ATR): ν˜ (cm−1) = 2985, 2955,
2925, 1762, 1720, 1468, 1410, 1364, 1326, 1258, 1228, 1113,
1090, 1018, 901, 838, 792, 770, 722, 604, 530; MS (ESI): m/z (%)
= 381.9 (100) [MH+], 763.2 (10) [2MH+]; HRMS (ESI): calcd for
C20H20N3O5 [MH
+] 382.1397, found 382.1403.
27a: Rf = 0.27 (PE–EtOAc 1 : 1); [α]
20
D = −12.4 (DCM, c = 1.0);
1H-NMR (300 MHz, CDCl3): δH = 8.03 (d, J = 1.2 Hz, 1H), 7.83
(dd, J = 5.5, 3.0 Hz, 2H), 7.70 (dd, J = 5.5, 3.0 Hz, 2H), 7.24 (t,
J = 1.0 Hz, 1H), 5.36 (t, J = 7.7 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H),
4.05 (dd, J = 6.2, 0.9 Hz, 1H), 3.51 (dd, J = 14.3, 7.1 Hz, 1H),
3.38 (dd, J = 14.3, 8.2 Hz, 1H), 2.59 (ddd, J = 12.9, 8.4, 7.1 Hz,
1H), 2.07 (ddd, J = 12.7, 7.2, 1.6 Hz, 1H), 1.76 (ddd, J = 7.0, 3.9,
1.5 Hz, 1H), 1.57–1.48 (m, 1H), 1.40 (t, J = 7.1 Hz, 3H),
1.30–1.20 (m, 1H); 13C-NMR (75 MHz, CDCl3): δC = 168.45 (Cq),
148.65 (Cq), 145.26 (Cq), 137.27 (+), 134.06 (Cq), 132.31 (+),
123.37 (+), 113.43 (+), 82.36 (+), 65.09 (+), 64.54 (−), 38.00 (−),
35.03 (−), 30.67 (+), 23.63 (+), 14.28 (+); IR (ATR): ν˜ (cm−1) =
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2977, 2931, 1760, 1711, 1467, 1433, 1409, 1391, 1357, 1336,
1253, 1211, 1137, 1102, 1019, 950, 846, 769, 721, 614, 530; MS
(ESI): m/z (%) = 381.9 (100) [MH+], 763.3 (75) [2MH+]; HRMS
(ESI): calcd for C20H20N3O5 [MH
+] 382.1397, found 382.1396.
Preparation of ethyl 5-((1S,3S,5S,6R)-6-((1,3-dioxoisoindolin-
2-yl)methyl)-2-oxabicyclo[3.1.0]hexan-3-yl)-1H-imidazole-1-car-
boxylate (27b). DIAD (54 mg, 0.25 mmol, 1.5 equiv.) was
added to a solution of PPh3 (65.5 mg, 0.25 mmol, 1.5 equiv.) in
anhydrous THF (1.3 mL) at room temperature under a nitrogen
atmosphere. After stirring for 10 min phthalimide (37 mg,
0.25 mmol, 1.5 equiv.) was added and stirred for another
10 min. After addition of alcohol 26b (42 mg, 0.17 mmol) the
reaction mixture was stirred for 18 h. The solvent was evapor-
ated under reduced pressure. The residue was purified by
column chromatography (PE–EtOAc 3 : 1 to 1 : 1) to obtain
compound 27b (17 mg, 0.04 mmol, 27%) as a colorless oil.
Rf = 0.43 (PE–EtOAc 1 : 3); [α]
20
D = +17.1 (DCM, c = 0.2);
1H-NMR (400 MHz, CDCl3): δH = 8.07 (d, J = 1.3 Hz, 1H),
7.90–7.82 (m, 2H), 7.76–7.67 (m, 2H), 7.30 (s, 1H), 4.68 (t, J =
8.0 Hz, 1H), 4.45 (q, J = 7.1 Hz, 2H), 4.11 (dd, J = 5.7, 1.2 Hz,
1H), 3.54 (dd, J = 14.2, 6.9 Hz, 1H), 3.42 (dd, J = 14.3, 7.8 Hz,
1H), 2.36–2.19 (m, 2H), 1.73–1.62 (m, 1H), 1.48–1.38 (m, 1H),
1.41 (t, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δC = 168.50
(Cq), 148.68 (Cq), 143.44 (Cq), 137.38 (+), 134.12 (+), 132.33
(Cq), 123.43 (+), 113.93 (+), 75.15 (+), 64.59 (−), 63.38 (+), 38.09
(−), 34.48 (−), 21.89 (+), 21.56 (+), 14.30 (+); IR (ATR): ν˜ (cm−1)
= 2978, 2936, 2873, 1758, 1707, 1467, 1391, 1336, 1251, 1139,
1087, 1017, 944, 850, 769, 721, 611, 541, 501; MS (ESI): m/z (%)
= 381.9 (100) [MH+], 763.3 (10) [2MH+]; HRMS (ESI): calcd for
C20H20N3O5 [MH
+] 382.1397, found 382.1405.
Preparation of 2-(((1S,3R,5S,6R)-3-((tert-butyldimethylsilyl-
oxy)methyl)-2-oxabicyclo[3.1.0]hexan-6-yl)-methyl)isoindoline-
1,3-dione (30), 2-((2R,3S,5R)-5-((tert-butyldimethylsilyloxy)-
methyl)-3-vinyltetra-hydrofuran-2-yl)isoindoline-1,3-dione (31a),
2-((2S,3S,5R)-5-((tert-butyldimethylsilyloxy)-methyl)-3-vinyltetra-
hydrofuran-2-yl)isoindoline-1,3-dione (31b), and (R)-tert-butyl-
dimethyl((4-vinyl-2,3-dihydrofuran-2-yl)methoxy)silane (32).
DIAD (1.58 g, 8.72 mmol, 1.5 equiv.) was added dropwise to a
solution of alcohol 19 (1.50 g, 5.82 mmol), PPh3 (2.29 g,
8.72 mmol, 1.5 equiv.) and phthalimide (1.28 mg, 8.72 mmol,
1.5 equiv.) in anhydrous THF (116 mL) at 50 °C. After stirring
at 50 °C for 1 h the mixture was cooled to room temperature
quenched with water (50 mL). The phases were separated and
the organic layer was extracted with DCM (3 × 25 mL). The
combined organic layers were dried over MgSO4, filtered and
concentrated in vacuo. The residue was purified by column
chromatography (PE–EtOAc 9 : 1, then 5 : 1) to obtain com-
pound 32 (100 mg, 0.42 mmol, 7%) as a colorless oil and com-
pound 31b (115 mg, 0.30 mmol, 5%), compound 31a (1.04 g,
2.67 mmol, 46%) and compound 30 (665 mg, 1.72 mmol,
29%) as colorless solids.
32: Rf = 0.59 (PE–EtOAc 9 : 1); [α]
20
D = −125.8 (DCM, c = 1.0);
1H-NMR (300 MHz, CDCl3): δH = 6.46 (ddd, J = 18.0, 11.0,
0.6 Hz, 1H), 6.41 (m, 1H), 4.85 (dd, J = 10.7, 1.1 Hz, 1H),
4.85–4.76 (m, 1H), 4.70 (dddd, J = 10.5, 7.3, 5.9, 4.9 Hz, 1H),
3.73 (dd, J = 10.9, 5.9 Hz, 1H), 3.65 (dd, J = 10.9, 4.8 Hz, 1H),
2.73 (dddd, J = 14.4, 10.4, 1.8, 0.7 Hz, 1H), 2.48 (dddd, J = 14.6,
7.3, 1.7, 0.6 Hz, 1H), 0.89 (s, 9H), 0.07 (s, 3H), 0.07 (s, 3H);
13C-NMR (75 MHz, CDCl3): δC = 144.97 (+), 129.08 (+), 116.31
(Cq), 109.70 (−), 83.00 (+), 65.64 (−), 30.71 (−), 26.01 (+), 18.50
(Cq), −5.14 (+), −5.19 (+); IR (ATR): ν˜ (cm−1) = 2955, 2929, 2857,
1641, 1472, 1463, 1253, 1105, 1006, 980, 834, 776, 667.
31b: Rf = 0.40 (PE–EtOAc 5 : 1); [α]
20
D = +95.5 (DCM, c = 0.5);
1H-NMR (300 MHz, CDCl3): δH = 7.83 (dd, J = 5.6, 3.0 Hz, 2H),
7.72 (dd, J = 5.6, 3.0 Hz, 2H), 6.13 (d, J = 8.4 Hz, 1H), 5.62 (ddd,
J = 17.5, 10.2, 7.5 Hz, 1H), 5.15 (dt, J = 17.1, 1.4 Hz, 1H), 4.99
(ddd, J = 10.2, 1.5, 1.0 Hz, 1H), 4.18 (ddt, J = 10.7, 6.5, 5.2 Hz,
1H), 3.97 (dd, J = 10.5, 6.6 Hz, 1H), 3.82 (dd, J = 10.5, 4.9 Hz,
1H), 3.41–3.26 (m, 1H), 2.39 (dt, J = 12.1, 11.2 Hz, 1H), 2.13
(ddd, J = 11.7, 7.6, 5.5 Hz, 1H), 0.89 (s, 9H), 0.07 (s, 3H), 0.06
(s, 3H); 13C-NMR (75 MHz, CDCl3): δC = 167.89 (Cq), 134.26 (+),
134.12 (+), 131.99 (Cq), 123.50 (+), 118.46 (−), 83.27 (+), 82.56
(+), 65.93 (−), 47.39 (+), 34.02 (−), 26.14 (+), 18.62 (Cq), −5.04
(+), −5.11 (+); IR (ATR): ν˜ (cm−1) = 2956, 2928, 2857, 1787,
1772, 1720, 1470, 1416, 1370, 1351, 1327, 1255, 1117, 1101,
1059, 1005, 924, 891, 838, 777, 720; MS (ESI): m/z (%) = 388.0
(100) [MH+], 729.4 (15) [2MH+]; HRMS (ESI): calcd for
C21H30NO4Si [MH
+] 388.1939, found 388.1941.
31a: Rf = 0.38 (PE–EtOAc 5 : 1); [α]
20
D = −41.5 (DCM, c = 1.0);
1H-NMR (300 MHz, CDCl3): δH = 7.84 (dd, J = 5.6, 3.0 Hz, 2H),
7.72 (dd, J = 5.6, 3.0 Hz, 2H), 5.79 (ddd, J = 17.1, 10.2, 8.0 Hz,
1H), 5.74 (d, J = 7.6 Hz, 1H), 5.09 (dt, J = 17.7, 1.4 Hz, 1H), 5.04
(ddd, J = 7.9, 1.4, 0.9 Hz, 1H), 4.53 (dq, J = 5.2, 4.1 Hz, 6H),
3.87–3.73 (m, 7H), 3.73 (dd, J = 11.0, 4.2 Hz, 10H), 3.67 (dd, J =
11.0, 4.4 Hz, 1H), 2.35 (ddd, J = 12.6, 7.6, 5.3 Hz, 1H), 1.89
(ddd, J = 12.2, 11.1, 10.1 Hz, 1H), 0.90 (s, 9H), 0.07 (s, 3H), 0.06
(s, 3H); 13C-NMR (75 MHz, CDCl3): δC = 167.95 (Cq), 136.90 (+),
134.31 (+), 132.06 (Cq), 123.57 (+), 117.25 (−), 85.23 (+), 80.85
(+), 65.07 (−), 46.15 (+), 35.26 (−), 26.08 (+), 18.51 (Cq), −5.10
(+), −5.21 (+); IR (ATR): ν˜ (cm−1) = 2954, 2929, 2857, 1775,
1717, 1470, 1405, 1368, 1328, 1253, 1084, 996, 921, 872, 836,
777, 718, 665, 530; MS (ESI): m/z (%) = 388.0 (70) [MH+], 405.0
(70) [MNH4
+], 775.4 (20) [2MH+], 792.4 (100) [2MNH4
+]; HRMS
(ESI): calcd for C21H30NO4Si [MH
+] 388.1939, found 388.1942.
30: mp = 63–65 °C; Rf = 0.25 (PE–EtOAc 5 : 1); [α]
20
D = +28.9
(DCM, c = 1.0); 1H-NMR (300 MHz, CDCl3): δH = 7.79 (dd, J =
5.5, 3.0 Hz, 2H), 7.67 (dd, J = 5.4, 3.1 Hz, 2H), 4.46–4.34 (m,
1H), 3.89 (dd, J = 6.2, 0.6 Hz, 1H), 3.47 (dd, J = 14.3, 6.9 Hz,
1H), 3.41 (d, J = 4.9 Hz, 2H), 3.28 (dd, J = 14.3, 8.4 Hz, 1H),
2.20 (ddd, J = 12.7, 8.1, 7.3 Hz, 1H), 1.70–1.53 (m, 2H),
1.36–1.25 (m, 1H), 0.82 (s, 9H), −0.02 (s, 6H); 13C-NMR
(75 MHz, CDCl3): δC = 168.28 (Cq), 133.94 (+), 132.23 (Cq),
123.22 (+), 87.79 (+), 65.97 (−), 64.86 (+), 37.87 (−), 31.45 (−),
31.13 (+), 25.97 (+), 23.09 (+), 18.42 (Cq), −5.30 (+), −5.31 (+); IR
(ATR): ν˜ (cm−1) = 2955, 2929, 2856, 1772, 1712, 1468, 1433,
1391, 1356, 1330, 1253, 1188, 1137, 1088, 1007, 990, 950, 836,
777, 720, 529; MS (ESI): m/z (%) = 388.1 (50) [MH+], 405.0 (100)
[MNH4
+]; HRMS (ESI): calcd for C21H30NO4Si [MH
+] 388.1939,
found 388.1940.
Preparation of (1S,3R,5S,6S)-methyl 3-(oxazol-5-yl)-2-oxabicy-
clo[3.1.0]hexane-6-carboxylate (33). To a solution of oxazoline
16 (396 mg, 1.04 mmol) in anhydrous MeOH (10 mL), K2CO3
Paper Organic & Biomolecular Chemistry
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(289 mg, 2.09 mmol, 2 equiv.) was added under a nitrogen
atmosphere. The reaction mixture was refluxed for 30 min,
quenched with water (15 mL) and extracted with DCM (3 ×
15 mL). The combined organic layers were dried over MgSO4,
filtrated and concentrated in vacuo. Purification by column
chromatography (PE–EtOAc 1 : 1) aﬀorded compound 33
(67 mg, 0.32 mmol, 31%) as a colorless solid.
Mp = 61 °C; Rf = 0.36 (PE–EtOAc 1 : 3); [α]
20
D = +30.6 (DCM,
c = 1.0); 1H-NMR (300 MHz, CDCl3): δH = 7.84 (s, 1H), 6.97 (s,
1H), 5.47 (dd, J = 9.4, 6.1 Hz, 1H), 4.30 (dd, J = 5.9, 0.6 Hz, 1H),
3.65 (s, 3H), 2.72 (ddd, J = 13.4, 9.5, 6.6 Hz, 1H), 2.37–2.30 (m,
1H), 2.26 (ddd, J = 13.5, 6.1, 0.7 Hz, 1H), 1.98 (dd, J = 3.9, 0.9
Hz, 1H); 13C-NMR (75 MHz, CDCl3): δC = 170.80 (Cq), 151.63
(Cq), 151.51 (+), 124.18 (+), 77.16 (+), 67.36 (+), 51.89 (+), 33.00
(−), 31.18 (+), 27.25 (+); IR (ATR): ν˜ (cm−1) = 3435 (br), 3129,
2954, 1716, 1507, 1440, 1394, 1311, 1274, 1198, 1171, 1107,
1070, 963, 860, 715; MS (EI): m/z (%) = 95.0 (100), 180.1 (39)
[M+ΔCHO], 209.1 (<1) [M+˙]; HRMS (EI): calcd for C10H11NO4
[M+˙] 209.0688, found 209.0694.
Preparation of (1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo-
[3.1.0]hexan-6-yl)methanol (34). To a stirred ice-cooled solu-
tion of oxazole 33 (65 mg, 0.31 mmol) in anhydrous THF
(3 mL) under a nitrogen atmosphere, LAH (9.3 mg, 0.25 mmol,
0.8 equiv.) was added in small portions within 5 min. The reac-
tion mixture was stirred for 30 min at 0 °C. After addition of
water (10 µL) the mixture was stirred for another 30 min. Then
a 15% aqueous NaOH solution (10 µL) was added followed by
water (30 µL). The mixture was warmed to room temperature,
treated with MgSO4 and filtered through a Celite pad. The
solvent was evaporated under reduced pressure. The crude
product was purified by column chromatography (EtOAc) to
obtain compound 34 (40 mg, 0.22 mmol, 71%) as a colorless
solid.
Mp = 95 °C; Rf = 0.19 (EtOAc); [α]
20
D = +25.8 (DCM, c = 1.0);
1H-NMR (400 MHz, CDCl3): δH = 7.81 (s, 1H), 6.93 (s, 1H), 5.41
(dd, J = 8.4, 6.9 Hz, 1H), 3.90 (dd, J = 6.2, 1.2 Hz, 1H), 3.39 (dd,
J = 11.6, 7.2 Hz, 1H), 3.33 (dd, J = 11.5, 7.1 Hz, 1H), 2.59 (ddd,
J = 13.0, 8.7, 6.9 Hz, 1H), 2.13 (ddd, J = 13.0, 6.7, 1.4 Hz, 1H),
2.11 (br s, 1H), 1.69–1.62 (m, 1H), 1.40 (tdd, J = 7.1, 4.0, 1.2 Hz,
1H); 13C-NMR (75 MHz, CDCl3): δC = 152.18 (Cq), 151.31 (+),
123.62 (+), 78.11 (+), 64.70 (+), 62.12 (−), 33.85 (−), 33.45 (+),
22.08 (+); IR (ATR): ν˜ (cm−1) = 3369 (br), 3125, 2945, 2881,
1508, 1461, 1414, 1353, 1262, 1176, 1106, 1026, 990, 966, 910,
885, 846, 645; MS (CI): m/z (%) = 182.1 (99) [MH+], 199.1 (100)
[MNH4
+]; HRMS (LSI): calcd for C9H12NO3 [MH
+] 182.0817,
found 182.0816.
Preparation of 2-(((1S,3R,5S,6R)-3-(oxazol-5-yl)-2-oxabicyclo-
[3.1.0]hexan-6-yl)methyl)isoindoline-1,3-dione (35). DIAD
(96 mg, 0.45 mmol, 1.5 equiv.) was added dropwise to a solu-
tion of oxazole 34 (54 mg, 0.30 mmol), PPh3 (117 mg,
0.45 mmol, 1.5 equiv.) and phthalimide (66 mg, 0.45 mmol,
1.5 equiv.) in anhydrous THF (6 mL) at 0 °C under a nitrogen
atmosphere. After stirring at 0 °C for 30 min the mixture
was allowed to warm to room temperature and the solvent
was evaporated under reduced pressure. The residue was puri-
fied by column chromatography (PE–EtOAc 3 : 1 to EtOAc) to
obtain compound 35 (51 mg, 0.17 mmol, 55%) as a colorless
solid.
Mp = 83 °C; Rf = 0.51 (EtOAc); [α]
20
D = +18.9 (DCM, c = 1.0);
1H-NMR (300 MHz, CDCl3): δH = 7.84 (dd, J = 5.5, 3.1 Hz, 2H),
7.79 (s, 1H), 7.72 (dd, J = 5.5, 3.1 Hz, 2H), 6.92 (s, 1H),
5.45–5.37 (m, 1H), 4.08 (dd, J = 6.3, 1.0 Hz, 1H), 3.56 (dd, J =
14.4, 6.9 Hz, 1H), 3.36 (dd, J = 14.4, 8.4 Hz, 1H), 2.59 (ddd, J =
13.1, 8.6, 7.1 Hz, 1H), 2.09 (ddd, J = 13.1, 7.2, 1.4 Hz, 1H),
1.84–1.75 (m, 1H), 1.59–1.51 (m, 1H); 13C-NMR (75 MHz,
CDCl3): δC = 168.33 (Cq), 151.59 (Cq), 151.30 (+), 134.08 (+),
132.18 (Cq), 123.87 (+), 123.36 (+), 78.48 (+), 65.23 (+), 37.73
(−), 33.92 (−), 30.69 (+), 23.24 (+); IR (ATR): ν˜ (cm−1) = 3141,
3938, 1769, 1708, 1509, 1467, 1433, 1392, 1357, 1329, 1260,
1225, 1197, 1136, 1101, 1071, 1026, 950, 851, 798, 720, 645,
531; MS (EI): m/z (%) = 77.1 (8), 95.1 (100), 104.1 (6), 130.1 (6),
160.1 (18), 310.1 (1) [M+˙]; HRMS (EI): calcd for C17H14N2O4
[M+˙] 310.0954, found 310.0956.
Preparation of methyl-N′-cyano-N-(((1S,3R,5S,6R)-3-(oxazol-5-
yl)-2-oxabicyclo[3.1.0]hexan-6-yl)methyl)carbamimido-thioate
(36). A solution of aminooxazole 9a (19 mg, 0.11 mmol) and
dimethyl N-cyanodithioiminocarbonate (34 mg, 0.22 mmol,
2 equiv.) in EtOH was stirred at room temperature for 18 h.
The solvent was evaporated under reduced pressure. The crude
product was purified by column chromatography (DCM then
DCM–MeOH 9 : 1) to aﬀord compound 36 (29 mg, 0.11 mmol,
quantitative) as a colorless oil.
Rf = 0.51 (PE–EtOAc 9 : 1); [α]
20
D = +14.3 (DCM, c = 1.0);
1H-NMR (300 MHz, CDCl3): δH = 7.84 (s, 1H), 7.16 (s, 0.5H),
6.96 (s, 1H), 6.53 (s, 0.5H), 5.43 (dd, J = 8.4, 7.2 Hz, 1H), 3.96
(dd, J = 6.3, 0.9 Hz, 1H), 3.45–2.86 (m, signal broadening due
to rotamers, 2H), 2.73–2.32 (m, signal broadening due to rota-
mers, 3H), 2.62 (ddd, J = 13.0, 8.6, 7.0 Hz, 1H), 2.15 (dd, J =
13.0, 6.9 Hz, 1H), 1.77–1.68 (m, 1H), 1.50–1.37 (m, 1H);
13C-NMR (75 MHz, CDCl3): δC = 151.67 (Cq), 151.44 (+), 123.99
(+), 78.34 (+), 64.99 (+), 44.01 (signal broadening due to rota-
mers, −), 33.82 (−), 30.09 (+), 23.30 (+), 14.64 (signal broaden-
ing due to rotamers, +), CvN and CuN signals too weak to be
observed; IR (ATR): ν˜ (cm−1) = 3263 (br), 3126, 3011, 2939,
2174, 1716, 1554, 1511, 1430, 1357, 1285, 1182, 1104, 938, 846,
645; MS (ESI): m/z (%) = 279.0 (30) [MH+], 296.0 (40) [MNH4
+],
557.1 (100) [2MH+]; HRMS (EI): calcd for C12H14N4O2S [M
+˙]
278.0837, found 278.0833.
Pharmacology
Histamine dihydrochloride was purchased from Alfa Aesar
GmbH & Co. KG (Karlsruhe, Germany). [3H]Nα-methylhista-
mine and [3H]histamine were from Perkin Elmer Life Sciences
(Boston, MA). Guanosine diphosphate (GDP) was from Sigma-
Aldrich Chemie GmbH (Munich, Germany), and unlabeled
GTPγS was from Roche (Mannheim, Germany). [3H]pyrilamine
was purchased from Hartmann Analytic (Braunschweig,
Germany). [35S]GTPγS was from PerkinElmer Life Sciences
(Boston, MA) or Hartmann Analytic GmbH (Braunschweig,
Germany). [3H]UR-DE257 (N-(6-(3,4-dioxo-2-(3-(3-(piperidin-1-
ylmethyl) phenoxy)propylamino)-cyclobut-1-enylamino)hexyl)-
[2,3-3H]-propionamide) was synthesized in our laboratory.31
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GF/C filters were from Whatman (Gaithersburg, USA).
For liquid scintillation counting was used: PerkinElmer
MicroBeta2 2450 MicroplateCounter (Massachusetts, USA),
Brandel Harvester MWXRT-96TI, Brandel (Gaithersburg, USA).
Scintillation cocktail Rotiszint™ eco plus was from Carl Roth
GmbH & Co KG (Karlsruhe, Germany).
Radioligand binding experiments32 were performed on the
hH1R, hH2R, hH3R and hH4R as follows. H1R assays: Sf9 insect
cell membranes expressing the hH1R + RGS4 were employed;
H2R assays: Sf9 insect cell membranes expressing the hH2R
−Gsαs fusion protein were employed; H3R assays: Sf9 insect
cell membranes coexpressing the hH3R, mammalian Gαi2 and
Gβ1γ2 were employed, H4R assays: Sf9 insect cell membranes
coexpressing the hH4R, mammalian Gαi2 and Gβ1γ2 were
employed. The respective membranes were thawed and sedi-
mented by centrifugation at 4 °C and 13 000g for 10 min.
Membranes were resuspended in binding buﬀer (12.5 mM
MgCl2, 1 mM EDTA and 75 mM Tris/HCl, pH 7.4). Each well
(total volume 250 µL) contained 20 µg (hH1R), 28 µg (hH2R),
50 µg (hH3R), or 120 µg (hH4R) of membrane protein. Compe-
tition binding experiments were performed in the presence of
5 nM [3H]pyrilamine (hH1R), 30 nM [
3H]UR-DE257 (hH2R),
3 nM [3H]Nα-methylhistamine (hH3R) or 15 nM [
3H]histamine
(hH3R and hH4R) and increasing concentrations of unlabeled
ligands. Incubations were conducted for 60 min at 25 °C and
shaking at 250 rpm. Bound radioligand was separated from
free radioligand by filtration through 0.3% polyethyleneimine-
pretreated (PEI) GF/C filters, followed by three washes with
2 mL of cold binding buﬀer (4 °C) using a Brandel Harvester.
Filter-bound radioactivity was determined after an equili-
bration phase of at least 12 h by liquid scintillation counting.
Functional [35S]GTPγS assays33 were performed as pre-
viously described for the H3R
34 and H4R.
35 H3R assays: Sf9
insect cell membranes coexpressing the hH3R, mammalian
Gαi2 and Gβ1γ2 were employed. H4R assays: Sf9 insect cell
membranes coexpressing the hH4R, mammalian Gαi2 and
Gβ1γ2 were employed. The respective membranes were thawed,
sedimented by a 10 min centrifugation at 4 °C and 13 000g.
Membranes were resuspended in binding buﬀer (12.5 mM
MgCl2, 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4). Each assay
tube contained Sf9 membranes expressing the respective HR
subtype (15–30 μg protein per tube), 1 μM GDP, 0.05% (w/v)
bovine serum albumin, 0.2 nM [35S]GTPγS and the investigated
ligands (dissolved in millipore water or in a mixture (v/v) of
80% millipore water and 20% DMSO) at various concentrations
in binding buﬀer (total volume 250 μL). All H4R assays
additionally contained 100 mM NaCl. For the determination of
KB values (antagonist mode of the functional [
35S]GTPγS assay)
histamine was added to the reaction mixtures (final concen-
tration for H3/4R: 100 nM). Incubations were conducted for
90 min at 25 °C and shaking at 250 rpm. Bound [35S]GTPγS
was separated from free [35S]GTPγS by filtration through GF/C
filters, followed by three washes with 2 mL of binding buﬀer
(4 °C) using a Brandel Harvester. Filter-bound radioactivity was
determined after an equilibration phase of at least 12 h by
liquid scintillation counting. The experimental conditions
chosen ensured that not more than 10% of the total amount
of [35S]GTPγS added was bound to filters. Non-specific binding
was determined in the presence of 10 μM unlabeled GTPγS.
All data are presented as mean ± SEM of N independent
experiments performed in triplicate. Maximal responses
(intrinsic activities) were expressed as α-values. The α-value of
histamine was set to 1.00; α-values of other compounds were
referred to this value. IC50 values were converted to Ki and KB
values using the Cheng–Prussoﬀ equation.36 Ki values were
analyzed by nonlinear regression and best fit to one-site
(monophasic) competition isotherms. pKB values from the
functional [35S]GTPγS were analyzed by nonlinear regression
and best fit to sigmoidal dose-response curves (GraphPad
Prism 5.0 software, San Diego, CA).
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